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ABSTRACT

lll

Altered T Cell-Mediated Immunity and Infectious Factors in Autism
by
Yong Hu, Doctor of Philosophy
Utah State University, 2000
Major Professor: Gregory J. Podgorski
Department of Biology
Three major questions were addressed in this dissertation: 1) Do immune
abnormalities associated with autism primarily alter CD4+ T cell-mediated or humoral
immune responses? 2) Are specific T cell clones expanded in autism? 3) Which, if any,
infectious agents play a role in autism?
CD4+ T cell-mediated (Thl) or humoral (Th2) immune responses can be
distinguished on the basis of the cytokines expressed. CD4+ T-cells secrete interleukin
type 2 (IL-2) and interferon-y, whereas a Th2 response is associated with secretion of
interleukin type 4 (IL-4). mRNA extracted from peripheral blood mononuclear nuclear
cells (PBMC) showed significantly increased levels of IL-2 and interferon-y expression in
24 autistic subjects relative to 19 normal controls. IL-4 mRNA was undetectable in the
same group of autistic subjects. These results indicate that a CD4+ T cell-mediated
immune response is associated with autism.
The expression of V-P chain mRNA was used as a marker of particular T cell
clone expression. The expression of V-P 13 was significantly elevated in the study group

of11 autistic subjects, but not in 9 normal subjects. This suggests that T cell-mediated
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autoimmunity is a factor in the disease. Two types ofhuman leukocyte antigens (HLA)
alleles, DR4 and DRl, are associated with autism. The association between V-B 13
expressing T cell clones and autism was shown even more strongly in the subgroup
expressing HLA DR4 or DRl. This result suggests a link between antigen presentation by
HLA DR4 or DRl and expansion ofV-B 13 T cell clones.
The potential involvement ofpathogens suspected to trigger autism was
investigated by examining T cell proliferation responses to peptide epitopes. As a group,
the 24 autistic subjects did not show a decreased response to peptides derived from
rubella virus, influenza A virus, herpes simplex virus type 1, cytomegalovirus, and
Clostridium tetani. Another model ofautism postulates that autism is induced by
pathogens that possess epitopes identical to the hypervariable region 3 (HVR-3) ofthe
HLA DR4 or DRl alleles. Two antigens derived from the Escherichia coli dna J protein
and the Epstein-Barr virus glycoprotein 110 peptides that contain sequences identical to
the HVR-3 ofthe DR4 and DRl alleles were examined for their ability to induce T cell
proliferation in autistic and normal subjects. No effect ofthe DR4 or DRl alleles on the
response to these two antigens was detected. Therefore, both types ofresults do not
support the model ofimmune tolerance in autism. However, average T cell proliferative
activity was significantly lower in the same autistic subjects. This confirms many prior
reports that reduced T-cell responses may shape susceptibility to autism.
Further understanding ofhow immune abnormalities and infectious agents lead to
autism should guide development ofpreventive and therapeutic strategies for this disease.
(152 pages)
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CHAPTER I
INTRODUCTION AND PROJECT OUTLINE
AN OVERVIEW OF AUTISM
Autism, also called infantile autism or autistic disorder, is a developmental
disorder of unknown etiology. Clinically, autism is characterized by obvious deficits in
the ability to interact and communicate. The primary symptoms of autism are poor social
development and communication, fixed imagination, and a limited scope of activities and
interests (Gillberg, 1990). Most researchers now believe that autism is a multifactorial
disorder (Gillberg and Coleman, 1992).
Autism is found throughout the world regardless of racial, ethnic, or social
background. In the U.S., it occurs in 0.03-0.05% of the general population (American
Psychiatric Association, 1994). There is a biased gender ratio in autism with 3-5 times as
many males diagnosed with the disease (Rutter, 1978). Although autism affects males
more frequently, symptoms in females are often more severe. Familial studies indicate
that about 3% of the siblings of autistic subjects are also affected by autism, a 50-fold
increase over the frequency seen in the general population (Folstein, 1985; Bolton and
Rutter, 1990).
Like most developmental disorders, the symptoms of autism are age-sensitive.
Autism is usually diagnosed when a child is 2 or 3 years of age (Rutter, 1978). During
infancy, an affected child does not make eye contact, smile, or engage in other forms of
communication with parents. In rare cases, the diagnosis of autism is made relatively late,
when problems with social interactions and language development become evident.

Current behavioral treatments are designed to promote social involvement and
improve communication skills (American Psychiatric Association, 1994). They usually
consist of language training and practice, family counseling, and sometimes include the
use of medication to control such symptoms as self-destructive behaviors, depression, or
agitation. Even with these measures the majority of autistic individuals are severely
impaired in adulthood. Only 1 in 50 patients with autism can work or live independently
(Shaner, 1997).
CLINICAL FEATURES OF AUTISM
The diagnosis of autism is based entirely on behavioral traits. Correct diagnosis
can be a challenge as autism is difficult to distinguish from other developmental disorders
such as Rett Syndrome and Asperger Syndrome. Rett Syndrome affects only females and
is apparent at a later age after normal early development (Gillberg and Coleman, 1992).
Asperger Syndrome presents social deficits similar to those of autism, but affected
individuals possess normal mental capacity and verbal and nonverbal communication
skills (Gillberg and Coleman, 1992).
The standard criteria for diagnosis of autism are given in the Diagnostic and
Statistical Manual of Mental Disorders of the American Psychiatric Association ( 1994).
According to this manual, the three abnormalities of autism are: 1) dysfunctional social
interactions and poor use of nonverbal communication; 2) poor use and understanding of
spoken language; 3) programmed behaviors and limited imagination as manifested by
rigid play formats and narrow interest scopes.
Minimal social participation or association is a striking feature of autism. Obvious

difficulties are seen using nonverbal communication through eye contact, facial
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expression, body posture, and gestures (Wing, 1980). Many autistic subjects also
experience heightened sensory stimulation that affects their perceptions of and responses
to their environment. As a consequence, autistic children react to stimuli in bewildering
ways. Emotional aspects of the disease, such as unwarranted anger or happiness and fear
of normally unprovocative stimuli, further inhibit normal social interactions.
Children with autism often have dramatic problems with verbal and nonverbal
communication. Errors in pronunciation and grammar coupled with difficulties
understanding verbal and body language are commonly observed (Bartak et al., 1975).
Some individuals have the ability to converse, but are impaired in their ability to initiate
or continue conversations. Rejection of imitative social actions and use of stereotypical
patterns of language are common characteristics of autism (Gillberg, 1990). These
communication deficits further isolate autistic children.
The interests of autistic subjects are limited. Attention often is fixed upon a single
object. Repetitive body movements and self-stimulating behavioral rituals, such as
rocking or scratching, also are common manifestations of autism.
More than 75% of children with autism meet definitions of mental retardation,
having an Intelligence Quotient (IQ) of< 70 (Lotter, 1966). About 40% of autistic
children have an IQ of less than 40. Ironically, about 10% of autistic subjects exhibit
extraordinary ability in one specific skill, such as memorization, mathematical
calculation, musical expression, or art. Unfortunately, the same autistic child may be
dysfunctional in other areas, unable to answer such basic questions as what did you eat
for dinner? Who was yesterday's playmate?

Occasionally, other medical conditions are associated with autism. These include
epilepsy (Taft and Cohen, 1971), vision and hearing impairments, fragile X syndrome
(Steffenburg and Gillberg, 1986; Gillberg, 1992), encephalitis, chromosome
translocation, maternal rubella, and tuberous sclerosis (Lotter, 1974).

BIOLOGY-BASED VIEWS OF AUTISM
Views of autism have evolved over the past 50 years from Kanner's early concept
of autism as an outcome of poor parenting to more recent ideas of autism as a
multifactorial, biologically based disorder (Gillberg, 1992; Burger and Warren, 1998). A
synopsis of some of the major ideas of the etiology of autism is presented below. These
hypotheses are summarized in Figure 1.1.
Psychogenic Theory

Kanner (1943), the first investigator to describe autism as a defined
developmental disorder, believed autism resulted from parenting failure. He erroneously
thought that autistic children came primarily from upper class families and that parents of
autistic children failed to provide critical language training, social interactions, and
physical attachment to their children because of their preoccupation with professional or
social success. This idea came to be known as the psychogenic theory of autism.
Experimental evidence for Kanner' s theory came from the pioneering studies of
Harlow and McKinney (1971), who showed that rhesus monkey infants that were isolated
from parents and all other social contacts developed symptoms resembling human
infantile autism. Even when these animals were later released from isolation chambers
and returned to their mothers, most continued to display autism-like symptoms of social
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Fig. 1.1. Hypotheses for the etiology of autism.

V,

isolation, poor communication, abnormal, repetitive movements, and self-damaging

6

behavior.
Harlow and McKinney (1971) proposed that a lack of parental contact and social
stimulation caused underdevelopment of the brain. They hypothesized that parental touch
and emotional nourishment are essential to the normal development of the central
nervous system in infant monkeys and humans. This psychogenic theory of autism
became widely accepted.
Later studies revealed serious flaws in the psychogenic theory. A major
discrepancy between theory and reality was the finding that the autism rates were
independent of social class, economic status, patterns of feeding, language training,
general sensory stimulation, and the degree of parental emotional attachment and
nurturing (DeMyer et al., 1972).
Genetic Factors in Autism
A role for genetic factors was suggested by a study of concordance in mono- and
dizygotic twins (F olstein and Rutter, 1977; Folstein, 1985). The concordance of autism in
monozygotic twins is about 36%, while the concordance in same-sex dizygotic twins
approaches zero, arguing strongly for a role of genetic factors in the disease. The fact that
concordance in monozyogotic twins is not perfect is also significant because it points to
the existence of environmental factors in disease development. More recently, Warren
and colleagues indicated that immunogenetic factors play a significant role in the
development of autism (Warren et al., 1986). Human leukocyte antigen (HLA) DR
molecules present antigens to T effector cells and are essential for T cell function.

Particular HLA DR alleles were found at a much higher frequency in autism, suggesting
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that T cell functions are involved in the etiology of the disorder (Warren et al., 1992,
1996).
Dopamine Imbalance
High levels of the central nervous system (CNS) neurotransmitter dopamine have
been documented in a significant number of autistic individuals (Minderaa et al., 1989;
Barthelemy et al., 1989). Dopamine regulates many CNS functions, including memory,
hormone secretion, emotional status, and alertness. Dopamine levels in autistic
individuals are elevated because the activity of dopamine hydroxylase, the enzyme that
degrades dopamine, is reduced in the disease (Goldstein et al., 1976; Lake et al., 1977;
Cohen et al., 1977). Administration of dopamine analogs in some patients makes autistic
symptoms more severe, while drugs that lower dopamine have the opposite effect
(Campbell et al., 1976, 1978). These findings clearly implicate dopamine imbalances in
some autistic individuals.
Infectious Factors in Autism
Infections, especially viral infections, appear to be an important factor in autism.
Rimland (1964) first found that children infected by rubella virus developed autism.
Later, similar studies were reported by Desmond et al. (1967), Chess (1971), and
Freedman et al. (1977). Taken together, these studies indicate a nearly 200-fold increase
in the frequency of autism in rubella-infected children over that seen in the general
population (Chess, 1977). Subsequently, other viruses have been implicated in autism
through case studies. These include cytomegalovirus (CMV) (Stubbs, 1978), herpes

simplex virus 1 (HSV-1) (Ritvo et al., 1990), varicella-zoster virus (VZV) (Knobloch
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and Pasaminick, 1975), and human immunodeficiency virus type 1 (HIV-I) (Schmitt et
al., 1991). Infection by these viruses during either prenatal or postnatal development is
thought to be possibly involved in autism.
Immune system abnormalities and viral infections may interact in the etiology of
autism. In this scenario, viral infections early in life induce B or T cell abnormalities that
either cause autoimmUPity or allow pathogen persistence. In either event, the
consequence is CNS damage that may lead to autism. The studies reported in Chapter 2,
3 and 4 of this dissertation explore aspects of the potential interrelationship between
infection and immune abnormalities in autism.
Immune Defects in Autism
Immune system defects appear to be an important factor in autism. Two broad
classes of these defects have been investigated intensively during the past two decades:
immune tolerance induced by early pathogen exposure and autoimmune responses
directed against the CNS. The investigation of both forms of immune system abnormality
forms a major part of this dissertation.
The hypothesis that immune tolerance induced by infection is a factor in autism
came from the observation that a group of normal and autistic subjects revealed a striking
difference in the ability to produce antibodies against rubella vaccine. Stubbs (1976)
found that 6 of 15 of these autistic children did not produce antibodies against rubella
vaccination challenge whereas all eight normal controls produced antibodies after rubella
vaccination. Stubbs (1976) proposed that some cases of autism may result from immune

tolerance induced by prenatal or early postnatal rubella infection. This immune

9

tolerance is postulated to lead either to persistence of the original pathogen or
susceptibility to secondary infections. Persistent, low-level infection in immune-tolerant
individuals may result in the CNS damage leading to autism (Stubbs, 1976).
The existence of CNS autoimmune diseases such as multiple sclerosis (Kennedy
and Karpus, 1999) and Sydenham's chorea (Moore, 1996) prompted investigations of
autoimmunity in autism. Autoimmunity directed against at least two CNS components
has been discovered in autistic patients. Weizman et al. (1982) found T cell-mediated
immune responses to human myelin basic protein in 13 of 17 autistic patients, but not in
any of 11 patients suffering from other mental disorders. This report is important because
it indicated that activated T cells are involved in autism and can target CNS struchlfal
proteins. Singh et al. (1993) independently found autoantibodies to myelin basic protein
in children with autism but not in normal controls. Finally, Todd and Ciaranello (1985)
discovered autoantibodies to CNS serotonin receptors in the cerebrospinal fluid of 7 of 15
autistic patients and in none of 15 normal controls. These studies provide compelling
evidence for the existence of autoimmunity in autistic individuals. The fact that activated
T cells easily cross the blood-brain barrier (Wekerie et al., 1986) strengthens models ofT
cell-mediated autoimmune damage to the CNS system as a cause of autism.
Findings that indicated immune abnormalities in autism sparked a series of
investigations into the cellular basis of these immune defects. These studies have
uncovered an array ofT cell alterations in autistic subjects. Stubbs et al. (1977) examined
lymphocyte proliferation stimulated by phytohemagglutin (PHA) as an indicator ofT cell
function. PHA primarily stimulates CD4+ T cells. The lymphocytes of autistic subjects
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displayed a significantly decreased proliferation response after stimulation with PHA
(Stubbs, 1976). A similar investigation performed by Warren and his coworkers
independently confirmed this finding (Warren et al., 1986).
Warren's group went on to investigate the activity of natural killer (NK) cells in
autism (Warren et al., 1987). NK cell activity provides non-specific immune protection
against viral infections and malignancy, and NK cells help to regulate immune responses.
In many autoimmune disorders, including multiple sclerosis (MS), rheumatoid arthritis
(RA), and Sjogren's syndrome (Sibbitt and Bankhurst, 1985; Takeda et al., 1987), NK
cell activity is decreased significantly. Warren et al. (1987) found that NK cell activity
was reduced in 12 of 31 patients with autism and none of23 normal individuals.
Two types of T cells are distinguished on the basis of their expression of the
CD4+ or CD8+ cell surface marker proteins. CD4+ T cells, also known as helper T cells,
work against intracellular antigens, and CD8+ T cells, also known as cytotoxic T cells,
target extracellular antigens. Warren et al. (1986) reported that patients with autism had a
reduced number of circulating CD4+ T cells, whereas numbers of CD8+ T cells were
normal. This finding was confirmed by Yonk et al. (1990).
Activated T cells express surface proteins, called HLA DR molecules, which
regulate T cell activation and T cell interactions. Warren et al. (1995) found that the DR+
marker was expressed in 14 of26 (53%) autistic subjects compared to only 3 of27 (11%)
age-matched healthy controls. Additionally, comparisons between age-matched DR+
autistic and normal individuals showed an 8-fold increase in the number ofDR+ T cells
in autistic subjects. This indicates that T cell activation occurs in autism and suggests
involvement of the immune system in the disease. A similar elevation of DR+ markers

has been reported in other autoimmune disorders (Effrench-Constant, 1994), including
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the autoimmune disease rheumatoid arthritis (Auger and Roudier, 1997).
The cytokine expression profiles of patients with autism are unusual and also
suggestive of immune system dysfunction. Cytokines are major mediators of immune
responsiveness. Singh and colleagues found elevated levels of interleukin type 2 (IL-2)
(Singh et al., 1991) and interleukin type 12 (IL-12) and interferon-y (Singh, 1996) in the
serum of autistic subjects. These results indicated the involvement of a class of helper T
cells, known as Thl cells. Gupta et al. (1998) also reported imbalances in cytokine levels
in autistic individuals and increased levels of interleukin type 4 (IL-4) were found which
is in contrast to the studies of Singh and his associates. These results suggest involvement
of Th2 helper T cells in autism. Chapter 2 of this dissertation reexamines this issue of a
role for Thl or Th2 cells in autism using a more sensitive methodology.
Finally, there is evidence of non-T cell immune abnormalities in autism. In a
search for abnormal B cell functions, Warren et al. (1997) uncovered lower serum levels
of imrnunoglobulin A (IgA) in 20% of autistic subjects studied. IgA is the major
imrnunoglobin secreted in the digestive tract, respiratory system, and milk. Warren and
colleagues also found decreased levels of circulating complement type 4B (C4B) in some
autistic patients (Warren et al., 1995). C4B is an important element of the complement
cascade and its downregulation would reduce the efficiency of antigen destruction.
THl VS TH2 CYTOKINES AND THEIR
IMPLICATION IN HUMAN DISEASES
Blood is a heterogeneous mixture containing red and white blood cells. About
25% of white blood cells are lymphocytes, key components of the specific immune

system (Geha et al., 1994). Among lymphocytes, B lymphocytes, or B cells, are
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responsible for humoral immunity, while T lymphocytes, also called T cells, control
cellular immunity.
Thl and Th2 Cytokines
There are distinct sets of T cells that perform different functions. CD8+ T cells,
also known as cytotoxic T cells, defend against extracellular microorganisms. Activated
cytotoxic T cells attack and kill these pathogens directly. CD4+ T cells, also called helper
T (Th) cells, activate macrophages and B cells. There are two major types of CD4+ T
cells, Thl and Th2 (Romagnani, 1992, 1995, 1996, 1997). Thl and Th2 cell types, their
functions, and the cytokines they produce are shown in Figure 1.2. Thl cells pick up cells
that are infected with granular intracellular antigens. Eventually, macrophages are
activated by Thl T cells to engulf the infected cell. Th2 cells detect extracellular
antigens, then activate B cells to produce specific antibodies. Thl and Th2 CD4+ T cells
produce distinct types of cytokines and these patterns of cytokine production are used
experimentally to distinguish the T helper cell types (Mosmann and Coffman, 1989;
Limaye et al., 1990). Thl cells primarily produce interferon-y and interleukin type 2 (IL2), whereas Th2 cells secrete IL-4 and IL-5 (Mosmann and Sad, 1996).
Role of Thl and Th2 Cytokines in Disease
Helper T cell abnormalities play a role in disease. Activated Thl cells are found
in affected tissues of disease that include MS (Laman et al., 1998; Windhagen et al.,
1998), RA (Miossec and van den Berg, 1997; Moore, 1999), autoimmune thyroid disease
(Martin et al., 1990), Crohn's disease (Raedler et al., 1986), and acute allograft rejection
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(De Carli et al., 1994). In animal models, adaptive transfer of activated Thl cells
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induces experimental autoimmune uveoretinitis and insulin-dependent diabetes (reviewed
by Liblau et al., 1995). Activated Th2 cells are present in tissues affected by progressive
systemic sclerosis and chronic graft-versus-host rejection (Krenger and Ferrara, 1996). In
all autoimmune diseases where helper T cells play a dominant role, cytokines in the
peripheral blood accurately indicate the type of helper T cell that infiltrates affected
tissues. For example, in animal models of multiple sclerosis, activated Thl cells are
found in the CNS (Link, 1998) and Th I-specific cytokines are elevated in the peripheral
blood (Okuda et al., 1998). Furthermore, in rheumatoid arthritis, distinct cytokine
patterns correlate well with the disease stages (Kanik et al., 1998).
Abnormal T helper cell activation may be involved in psychiatric disorders.
Abnormal cytokine levels are detected in the cerebrospinal fluid of children suffering
from obsessive disorder and schizophrenia (Mittleman et al., 1997). In autism, Singh et
al. discovered unusually high serum levels ofIL-2 and IL-12 (Singh et al., 1991; Singh
1996), indicating Thl cell activation. Gupta et al. (1998) also found cytokine elevation in
autism indicative of helper T cell activation, but saw an increase in IL-4, a marker of Th2
cell activation. The studies reported in Chapter 2 of this dissertation take an alternative
experimental approach to reexamine the question of Thl or Th2 cell activation in autism.

T CELL RECEPTOR REPERTOIRES IN
HUMAN DISEASES
The T Cell Receptor (TCR)
T cell receptors are transmembrane proteins that allow antigen recognition. The

predominate TCR is a heterodimer made of a and p chains, although TCRs composed
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of y and<> chains occur at lower frequency. The structure of the ap TCR heterodimer is
presented in Figure 1.3. Each T cell expresses only a single type of TCR heterodimer and
as a consequence recognizes a restricted set of antigens presented in the context of major
histocompatibilty complex (MHC) molecules present on the surface of antigen-presenting
cells (Geha et al., 1994). Binding of the antigen-MHC complex to the TCR activates or
inhibits T cell proliferation. Currently, 50 a and 60 p TCR chains are known (Spinella
and Robertson, 1994; Garcia et al., 1999). These allow formation of a huge number of
heterodimers that can recognize an even larger number of antigens (Imberti et al., 1993;
Arden et al., 1995; Vandenbark et al., 1996). Each polypeptide chain is composed of a
constant and a variable domain. The specificity of T cell-antigen interaction is due
primarily to the type of p chain that is expressed (Geha et al., 1994).
The TCR repertoire is determined by many factors, including genetic background.
Expansion of specific T cell clones is observed in many disease conditions, including T
cell-mediated autoimmune disorders, during infection (Islam et al., 1996) and stimulation
by superantigens. Expanded T cell clones are identified on the basis of the T cell
receptors they express, with the specific type of variable region of the p (V-P) chain
serving as a marker. Two methods are available for detection of specific V-P chains: flow
cytometry and reverse transcription-polymerase chain reaction (RT-PCR). RT-PCR has
the advantages of greater sensitivity and the ability to detect all major specific V -P chains
TCR, and is now the method of choice.

Intracellular region

Cytoplasm
Cell membrane

Transmembrane region
�

Disulfide bond

Hinge region

Carbohydrate

Constant region

a chain

� chain
Hypervariable region

Antigen binding region
Fig. 1.3. T cell receptor (TCR) structure.
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T cell clone expansion is a hallmark of autoimmune diseases. These documented
autoimmune diseases include MS (Wucherpfennig and Hafter, 1995; Lozeron et al.,
1998), type I diabetes (Atlan-Gepner et al., 1997), systemic lupus erythematosus
(Furukawa et al., 1996; Holbrook et al., 1996; Mato et al., 1997), sarcoidosis (Moller et

al., 1988), Kawasaki disease (Abe et al., 1993), microscopic polyarteritis (Simpson et al.,
1995), primary biliary cirrhosis, Sjogren' s syndrome, and RA (Jenkins et al., 1993). In
every one of these disorders, one or a few helper T cell clones form the predominant
activated T cell population. For example, T helper cells are known to infiltrate affected
nervous tissue of MS patients and RT-PCR has shown that these cells express V-P 8
almost exclusively. In RA, similar RT-PCR analysis shows that either V-P 14 or V-P 17
is expressed by the helper T cells collected from synovial fluid of affected joints. The
same V-P regions are expressed by the majority of helper T cells in peripheral blood of
RA patients, indicating a good correlation between expanded T cells populations in
peripheral blood and affected tissue. MS and RA provide two examples of autoimmune
diseases in which a specific T cell population is expanded. The studies reported in
Chapter 3 of this dissertation use RT-PCR of RNA isolated from peripheral blood to learn
if particular T cell clones are expanded in autism.
In animal models of autoimmune disorders, there is good evidence that T cell
clone expansion is a cause rather than a consequence of disease. Transfers of splenic T
cells from animals with experimentally induced type I diabetes er RA r�sults in the
development of the corresponding diseases in genetically compatible animals. In murine

experimental autoimmune thyroiditis, the unique and causative TCR V-P clones are
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also identified (McMurray et al., 1996).
The enhanced expression of specific cytokines and T cell clone expansion may be
related (Parronchi et al., 1991; Olsson et al., 1995). Initial stimulation of T cell clones by
exposure to antigens will induce specific patterns of cytokine secretion. In turn, these
cytokines feed back upon the initially stimulated T cell clone in an autocrine feedback
loop to further stimulate clonal expansion. This clonal expansion fueled by increased
cytokine expression may lead to autoimmune diseases. This model is supported by
investigations of MS where it was found that upregulation of Thi cytokine expression
and T cells clones expressing V-P 8 were interrelated in both MS patients and in animal
models of the disease (Olsson et al., 1995)
In addition to serving as a marker, the V-P region expressed by T cell clones
presents a target for therapy. In animal models of MS, administration of monoclonal
antibodies against V-P 8 decreased the severity of symptoms (Urban et al., 1988;
V andenbark et al., 1989; Acha-Orbea et al., 1988). Knowledge of potential T cell clones
that predominate in autism may offer the hope for similar therapy.
Susceptibility to most autoimmune diseases involves a significant genetic
component. An important genetic marker for susceptibility to any autoimmune disease is
the MHC genotype (Albani et al., 1992; Ikeda et al., 1996), especially alleles of the DR
locus. This locus encodes DR proteins that are key elements of the MHC that presents
antigens to T cells (Geha et al., 1994; Tuokko et al., 1998). Particular DR alleles occur at
high frequency in many autoimmune disorders (Geha et al., 1994; Tuokko et al., 1998).

For example, in MS DR2 is commonly present, in rheumatoid arthritis DR4

19

predominates, in type I diabetes DR3 and DR4 occur frequently, and in myasthenia
gravis, DR3 is frequently present. A very high frequency of DR4 or DRl is associated
with autism (Warren et al., 1995). The reasons behind the association between specific
DR alleles and autoimmune diseases are unknown, but one hypothesis is that particular
DR alleles present antigens derived from infectious pathogens in a manner that induces T
cells to target not only the foreign antigen but self-antigens as well (Ou et al., 1998,
1999; Williams et al., 1993). This leads to expansion of self-reactive T cell populations
that destroy host tissue.
INFECTIOUS AGENTS SUSPECTED
IN AUTISM
Epidemiological investigations and case studies both suggest a close link between
viral infections early in life and autism. These viruses include rubella (Rimland, 1964),
CMV (Stubbs, 1978), HSV-1 (Ritvo et al., 1990), VZV (Knobloch and Pasaminick,
1975), mumps (Deykin and Macmahon, 1979), and HIV-I (Schmitt et al., 1991). Rubella
is the strongest candidate pathogen in autism with other viruses implicated primarily
through case studies. The evidence for rubella virus, CMV, and HSV-1 as causative
agents of autism is discussed below.
Rubella Virus
After a rubella virus epidemic occurred in New York City, 243 infected children
were followed in a prospective study. Within this group 10 subjects developed autism
with full symptoms and 8 subjects with partial symptoms (Rimland, 1964). The infected

children were followed, and another 4 subjects were later diagnosed with autism

20

(Chess et al., 1978). This is a remarkably high frequency of autism, roughly 175-fold
greater than that of the general population. In another study of 210 rubella virus-infected
children, 7% were diagnosed with autism (Stubbs et al., 1977). Small-scale investigations
in Italy (Elia et al., 1990) and Utah (Ritvo et al., 1990) uncovered the same association
between childhood rubella virus infection and autism. An important point stemming from
these studies is that autism may develop either shortly (Freedman et al., 1977) or a
significant time after acute rubella virus infection (Pfefferbaum, 1996).
Rubella virus is best known for causing birth defects when infection occurs during
pregnancy (congenital rubella syndrome), especially during the first trimester. In
congenital rubella syndrome, rubella virus particles present in the maternal circulation
cross the placenta and damage the fetus (Lim et al., 1995; Lane et al., 1996). Rubella
virus infection also causes encephalitis that leads to cognitive, motor, and behavioral
deficits that are first seen in early infancy. Rubella-induced encephalitis is long lasting,
with infectious particles present in blood and cerebrospinal fluid 1 year after birth in 80%
of congenitally infected infants (Cradock-Watson et al., 1989; Katow, 1998). In vitro
studies also indicate that rubella virus attaches to human lymphocytes and substantially
decreases lymphocyte functions (Plotkin et al., 1965). Although the role of rubella
infections in autism is unknown, both CNS damage and alteration of lymphocytes
activity are two possibilities.
CMV
Congenital CMV infection is a significant health problem in the United States

(Starr et al., 1970). The view that CMV infection is a factor in autism comes from a
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series of case studies. Stubbs (1978) reported a case of an autistic patient who suffered
congenital CMV infection. He speculated that congenital CMV infection could have led to
the autistic symptoms probably through the same mechanisms that links rubella virus
infection and autism. In a prospective study of 72 infants congenitally infected by CMV
and followed for 3 years (Blattner, 1974), three cases of autism developed. In other studies,
maternal CMV infection during pregnancy was suspected to produce autism. In these cases,
congenital CMV infection of autistic children born to CMV-infected mothers was indicated
by the presence of antibodies to CMV, viral particles in urine, hearing loss, and damage to
the retina that appeared to be the result of CMV infection (Markowitz, 1983; Stubbs et al.,
1984; Ivarsson et al., 1990).
HSV-1
The case for HSV-1 in autism comes from case studies showing antibodies
against HSV-1 in autistic children and their mothers and an association between HSV-!
induced encephalopathy and autism. Like rubella virus and CMV, neonatal HSV-1
infection occurs commonly and affects about 5 per 10,000 of newborn infants in the U.S
(Brown et al., 1991). Delong and his associates were the first to report a possible link
between congenital HSV-1 infection and autism (Delong et al., 1981). In their study,
three boys with autism were found to have had congenital HSV-1 infection that led to
encephalopathy. These three individuals were asymptomatic for autism prior to their
HSY-I-induced encephalopathies. Neurological examinations revealed CNS damage in
two of these autistic children. In one case, damage to the left temporal lobe was found

and a high serum antibody titer for HSV-1 was detected. In another case, autism
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developed in a previously normal child 10 days after developing HSY-induced
encephalitis (Gillberg, 1986). Bilateral damage in the temporal lobes of the second
patient, presumably caused by HSV-1 infection, was also detected (Gillberg, 1986).
Finally, Ritvo et al. (1990) found two cases in which autistic children and their mothers
had antibodies against HSV-1 and speculated that there may be a causal relationship.
Vaccination
An abnormal response to vaccination has been suggested to be an important factor
in the etiology of autism. There are anecdotal reports of children developing autism
within months of immunization with measles-mumps-rubella (MMR) or diptheria
pertussis-tetanus (DPT) vaccines. Munyer et al. (1975) found that long-lasting, depressed
lymphocyte functions developed in some individuals after MMR vaccination, and Rossier

et al. (1994) reported an absence of cell-mediated immunity to rubella virus in 19 of 25
normal children 5 years after MMR vaccination. The generally depressed immune
function seen in autistic patients (Yonk et al., 1990; Warren et al., 1990) and these
observations of depressed immune functions following vaccination have led to the
hypothesis that some autistic individuals develop their symptoms as a consequence of
vaccine-induced immune depression (Campbell, 1989; McFarland, 1999). Possibly the
decreased immune functions induced in some individuals allow persistent secondary viral
infections that damage the CNS and lead to autism.
RESEARCH GOALS
This dissertation examined three questions related to immune abnormalities in the
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etiology of autism. The first question was which type of helper T cell, Thl or Th2, is
involved in the disease. Two previous works showed expansion of helper T cell
populations in autistic individuals, but came to conflicting conclusions regarding which
helper T cell type was involved (Gupta et al., 1998; Singh, 1996). The second question
was whether a particular T cell clone predominates in autistic individuals. This would
provide further evidence of altered T cell immune functions in autism. The final question
of this study asked if specific pathogens are involved in autism.
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CYTOKINE EXPRESSION PATTERNS INDICATE
A Thl TYPE OFT CELL RESPONSE IN AUTISM
ABSTRACT
Abnormal helper T cell function may underlie the pathology of autoimmune
disorders and some psychiatric diseases of children, including autism. Helper T cells
activate and inhibit a variety of other effector cells and are classified as Thl or Th2 types
based on the effector cells they control. Thl cells secrete interleukin type 2 (IL-2),
interferon-y and interleukin type 12 (IL-12), and Th2 cells secrete interleukin type 4 (IL4). Two previous reports have shown that helper T cells are involved in autism, but came
to conflicting conclusions regarding whether these were Th 1 or Th2 cells. In order to
clarify which type of helper T cell is associated with autism, we employed competitive
reverse transcription-based polymerase chain reaction (RT-PCR) to examine the profile
of cytokines expressed in autistic and normal individuals. The expression of interferon-y,
IL-2, and IL-4 mRNA was examined in phytohemagglutinin (PHA)-stimulated peripheral
blood mononuclear cells (PBMC) obtained from 24 autistic subjects and 19 normal
controls. Levels of interferon-y and IL-2 mRNA were significantly higher (p < 0.05 and p
< 0.0002, respectively) in the autistic group. IL-4 was detected in only 1 of 24 autistic
subjects and in 5 of 19 of normal individuals (p < 0.005). These results indicate that
activated Thl T cells are associated with autism.

INTRODUCTION
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Autism, also called infantile autism or autistic disorder, is a major pervasive
developmental disease with an occurrence of 0.03-0.05% in the general population
(Shaner, 1997). It is characterized by social isolation, language deficits, and narrow
activity and interest scopes. The etiology of autism is unknown, and multiple causes have
been postulated, including genetic factors (Folstein and Rutter, 1977; Folstein 1985),
neurological dan1age (DeMyer etal., 1972), immune dysfunction (Warren etal., 1986,
1987; Todd eta!., 1988; Singh eta!., 1993), and viral infections (Chess, 1977;
Matrkowitz, 1983). Immune abnormalities, especially T cell-mediated dysfunction (Yonk

etal., 1990), have been intensively investigated in autism. Abnormal T cell functions
(Stubbs etal., 1977; Weizman etal., 1982), T cell number (Warren etal., 1986, 1990),
and the helper/depression T cell ratio (Plioplys et al., 1994; Warren et al., 1995) are all
altered in autistic subjects.
CD4+ T cells, also known as helper T cells (Th), are at the core of T cell
mediated immunity. There are two distinct subpopulations of CD4+ T cells (reviewed by
Olsson, 1995). Thi cells activate macrophages, and inhibit B cells and are responsible for
acute rejection during organ transplantation and for elimination of intracellular
pathogens. Th2 cells activate B cells, and inhibit macrophages and cause antibody-related
autoimmune reactions. CD4+ T cells control effector cells largely through the cytokines
they secrete. The predominant cytokines secreted by Thi cells are interferon-y and IL-2
and the predominant cytokines secreted by Th2 cells are IL-4, interleukin type 5 (IL-5),
and interleukin type 10 (IL-10) (Mosmann and Sad, 1996). CD4+ T cell activation can
lead to autoimmune diseases in human and animal models. Thl cell activation is also

responsible for organ-specific autoimmune diseases that include experimental
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autoimmune uveoretinitis and insulin-dependent diabetes (reviewed in Liblau et al.,
1995), and Thl -specific cytokines such as IL-2 and interferon-y are detected in
autoimmune thyroiditis, type I insulin dependent diabetes mellitus, multiple sclerosis,
peptic ulcers, and Crohn's disease (reviewed by Romagnani, 1995, 1996, 1997; Adorini
and Sinigalia, 1997). In animal models, injection ofactivated Thi cells into naive animals
generates experimentai autoimmune encephalomyelitis (EAE) (reviewed in Fabry et al.,
1994). Altered levels ofThl- or Th2-specific cytokines have also been observed in
childhood obsessive-compulsive disorder and schizophrenia, suggesting an involvement
ofCD4+ T cells in these psychiatric diseases (Mittleman et al., 1997).
The potential involvement ofCD4+ T cells in autism has been investigated by
examining cytokine expression patterns either in serum or in PBMC. Singh and his
coworkers (Singh et al., 1991; Singh, 1996) reported that the Thl -specific cytokines IL-2,
IL-12, and interferon-y were elevated in the serum of autistic individuals, whereas Gupta
et al. (1998) reported that IL-4, a Th2-specific cytokine, was elevated in PBMC of
autistic subjects. In this paper, we reexamined the issue ofwhich type ofCD4+ T cell,
Thl or Th2, is involved in autism by using RT-PCR to measure IL-2, interferon-y, and
IL-4 mRNAs present in PBMC.
RT-PCR was chosen to assay cytokine expression because of its high sensitivity.
This technique has been widely utilized for studies of cytokine expression in human
autoimmune disorders (Di Fabio et al., 1994; Bost et al., 1995; Than et al., 1997). An
assumption of the method is that mRNA levels are a reflection of active cytokine. In
cases where this assumption has been examined, RNA levels have been shown to be a

good predictor of cytokine levels. For example, in a study of IL-10 expression in

41

different human T cell lines, mRNA levels detected by RT-PCR were well correlated
with IL-10 protein in serum, blood, and ascitic fluid as measured by enzyme-linked
immunosorbent assay (ELISA) (Bost et al., 1995).
The results reported here indicate that the Thi-specific cytokines IL-2 and
interferon-y were elevated in autistic subjects and that the Th2-specific cytokine IL-4 was
produced at detectable levels in only a single autistic individual. These results indicate
that Th l cells are activated in autism.
MATERIALS AND METHODS
Study Group
This study included 24 autistic (22 males and 2 females) and 19 normal subjects
(15 males and 4 females) (Table 2.1). Ages ranged from 2-19 years in the autistic group
and from 7-16 years in the normal group. Diagnosis of autism was made by child
psychiatrists according to parameters of American Psychiatric Association (1994).
Isolation of Total RNA
Blood was collected in heparin-coated tubes and peripheral blood mononuclear
cells (PBMC) were isolated by histopaque centrifugation. The cells were washed with
RPMI-1640, resuspended in 10% dimethyl sulfoxide and 90% fetal bovine serum (FBS),
and cryopreserved at-80°C. For analysis, PBMC were thawed and cultured in RPMI1640 supplemented with 10% FBS and 10 µg/ml PHA (Gibco, BRL) for 5 days at 37°C
in a humidified, 5% CO2 atmosphere. The PBMC were harvested and collected by

Table 2.1
Sex and Age of Subjects
Autistic
Subject
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
#15
#16
#17
#18
#19
#20
#21
#22
#23
#24

Sex

Age

M
M
M
F
F
M
M
M
M
M

2
2
3
4
5
5
5
6
7
7
7
7
8
8
9
11
11
11
12
13

M
M

M
M
M
M
M
M
M
M
M
M
M
M

13

14
16
19

Normal
Subject

Sex

Age

#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
#15
#16
#17
#18
#19

M
M
M
M
M
F
M
M
F
M
M
M
F
M
M
M
M
F
M

7
9
9
10
10
11
11
11
11
12
12
13
13
14
14
14
15
15
16

centrifugation and RNA was extracted from the pelleted cells using the Trizol RNA
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extraction kit according to the manufacturer's directions (Gibco, Gaithersburg, MD).
Quantification of Cytokine mRNAs
cDNA was synthesized by random hexamer priming with Moloney murine
leukemia virus reverse transcriptase (Promega, Madison, WI) using a kit according to
manufacturer's directions (Boehringer Mannheim, GmbH, Germany). To minimize
mRNA degradation, RNAase inhibitor at a final concentration of 1 unit/µl was added to
the cDNA synthesis reaction.
Interferon-y and IL-4 mRNA levels were determined by RT-PCR using
commercial kits purchased from Clontech (Palo Alto, CA). These kits use specific
"mimic" cDNAs added at known concentration to the reaction. The mimic cDNAs are
cloned versions of the interferon-y and IL-4 sequences that contain a small insertion to
distinguish their amplification products from that of the endogenous sequences. These
mimics and the cDNA synthesized from endogenous mRNA compete for the same primer
set and other components of the PCR system. The sequences of oligonucleotide primers
used in this study are given in Table 2.2. Precautions to avoid contamination in the PCR
included the use of aerosol barrier tips and RNase inhibitor treatment of pipets,
glassware, and bench surfaces. Negative controls lacking template DNA were included in
all PCR analyses. In no case was there evidence of spurious amplification.
For competitive RT-PCR of interferon-y and IL-4, 2 µl of cDNA synthesized
from PBMC mRNA was placed into five tubes. Each tube contained a primer pair and 2
µl of a 1 :3 dilution series of mimic cDNA with a starting amount 5.1 x 10 7 molecules of

Table 2.2
Oligonuleotide Primers Used in the Cytokine Study
Cytokine

Sequences

Interferon-y 5' 5'-GCATCGTTITGGGITCTCITGGCTGTTACTGC-3'
Interferon-y 3' 5'-CTCCTTTITCGCTTCCCTGITTTAGCTGCTGG-3'

PCR

Size

Mimic

427 bp

570 bp
504 bp

IL-4 5'
IL-4 3'

5'-CGGCAACITTGACCACGGACACAAGTGCGATA-3'
5'-ACGTACTCTGGITGGCITCCITCACAGGACAG-3'

344 bp

IL-2 5'
IL-2 3'

5'-AACTCCTGTCITGCAITGCA-3'
5'-GTGTTGAGATGATGCTITGAC-3'

441 bp

Actin 5'
Actin 3'

5'-ATGTTTGAGACCTTCAACAC-3'
5'-CACGTCACACTTCATGATGG-3'

489 bp

.i:,..
.i:,..

6

interferon-y and 5.6 x 10 molecules ofIL-4. Mimic cDNAs and primers were
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purchased from Clonetech (Palo Alto, CA). IL-2 mRNA levels were measured relative to
actin mRNA according the method ofHaraguchi et al. (1995). Actin mRNA expression is
assumed to be constitutive. Separate PCRs were performed to amplify IL-2 and actin
cDNA, but analyzed in the same condition.
PCR was performed in a 15-µl mixture containing 10 mM Tris (pH 8.3), 50 mM
KCl, 1.2 mM MgCh, 1 mM dNTP, 1 unit Taq DNA polymerase (Fisher Scientific,
Pittsburgh, PA) and 45 pmol ofeach primer pair. PCR was carried out with an initial 5minute denaturation at 94°C followed by 30 cycles ofthe following profile: 1 minute at
94°C, 1 minute at 64°C, and 2 minutes at 72°C. Pilot experiments were performed to
establish conditions under which the PCR remained in exponential phase. Four µl ofeach
PCR product was analyzed by electrophoresis through 1.5 % agarose gels. Gels were
stained with ethidium bromide, visualized under UV light, and photographed with
Polaroid 667 film.
The levels ofinterferon-y and IL-4 mRNA were determined by comparison
between the endogenous and mimic cDNA amplification products. Five different PCRs in
which each PCR containing a different dilution ofthe mimic cDNA were run for each
cytokine from each subject. Whenever the densities ofthe mimic and endogenous cDNA
products matched, this indicated that the starting target cDNA concentrations were equal
to that oftheir corresponding mimic cDNA. Tests ofthis method using a fixed and
known amount ofendogenous cDNA and varying amounts ofmimic cDNA verified the
accuracy ofthis method (data not shown). Relative levels ofIL-2 were determined by

comparison of the intensity of the amplification products ofthe IL-2 and actin mRNAs
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from the same individual. This ratio was termed arbitrary optical density units (AODU).
The photograph of the stained agarose gel was scanned and the intensities of the bands
were determined using a densitometer (Biosoft Image System, Ferguson, MO). Mean
values for each cytokine present in the autistic and normal groups were calculated and
evaluated for statistically significant differences using Student's t test.
The levels ofThl- and Th2-specific cytokine mRNAs in the autistic and normal
groups were compared in two different ways. In the first method, cytokine levels were
averaged for the autistic and normal groups and the significance of these differences was
analyzed using Student's t test. The second method compared the number of individuals
in each group that expressed a particular cytokine to any detectable level and the
significance of intergroup differences was assessed by the x,2 test. These independent
methods of analysis provide a measure of confidence regarding differences between
autistic and normal individuals.
RESULTS
Levels of the Th I-specific cytokines interferon-y and IL-2 are shown as scatter
plots in Figures 2.1 and 2.2, respectively, and are given in Table 2.3. Because interferon-y
mRNA levels varied widely in both groups, they are shown as log 10 -transformed values
in Figure 2.1. The mean level of interferon-y expression was 2.5-fold higher in the
autistic group and this difference from the normal group was significant (p < 0.05). As
for interferon-y, there also is considerable variability in IL-2 expression levels in both
groups. The autistic group expressed an average 3-fold higher level oflL-2 mRNA
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Fig. 2.2. Relative IL-2 mRNA expression in autistic and control groups. RT
PCR was performed as described in Methods. IL-2 mRNA expression is given as the
ratio of the IL-2 to actin PCR products in the same subject. The black horizontal bars (
) show the mean of the group, and the sample size in each group is given by the n
value.

Autistic subjects
(n= 24)

,

c

L-2/

Ra

Table 2.3
Cytokine Expression in Autistic and Normal Subjects
Interferon-y

IL-2

IL-4

Group

Autistic

Normal

Autistic

Normal

Autistic

Normal

No. Detectable

15/24

5/19

22/24

8/19

1/24

5/19

% detectable

63%

26%

92%

42%

4%

26%

2

x test
Da
µ± S
Student's t test
a

p < 0.005

P < 0.025
12400 ± 7900b

4500 ± 8200

b

P < 0.05

0.60± 0.43

c

0.18 ± 0.20

p < 0.0002

p < 0.005
c

b

240 ± 112b 1300± 1960
NA

d

Mean ± standard deviation.
Cytokine molecules/µg total RNA isolated from PBMC.
c
The ratio between IL-2 and actin mRNA expression.
d
Not applicable.
b

�
'°

than did the normal controls (p < 0.0002). The expression ofboth of major Thl-
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specific cytokines in the autistic group indicates that Thl CD4+ T cells are activated in
many autistic individuals.
Levels ofthe Th2-specific cytokine IL-4 mRNA are shown as a scatter plot in
Figure 2.3 and are given in Table 2.3. Only one ofthe autistic subjects and 5 ofthe
normal subjects expressed detectable levels oflL-4 mRNA. Because of the low numbers
of individuals expressing IL-4 in each group, Student's t test could not be used to analyze
these results.
As shown in Table 2.3, the numbers ofindividuals in each group who expressed
particular cytokines are also displayed. Interferon-y was detected in 15 of24 (62.5%)
autistic subjects and 5 of19 (26.3%) control subjects. This difference was significant (p <
0.025 by x 2). IL-2 was detected in 22 of24 (91.7%) autistic subjects and 8 of19 (42.1%)
normal controls. This difference was also significant (p < 0.005 by x2). In contrast to the
Th l -specific cytokines, a higher number of control subjects expressed the Th2-specific
cytokine IL-4 than did autistic subjects. Five of19 (26%) control subjects and 1 of24
(4%) autistic subjects expressed IL-4. This difference also was significant (p < 0.005 by
X 2).

The mean age for the autistic and normal study groups was 8.5 and 11.9 years,
respectively. Although Student's t test evaluation ofthis age difference indicated it was
not significant, the possibility that the elevated cytokine expression in the autistic group
was due to the younger average age ofthese individuals was examined. The levels of
IL-2 and interferon-y were plotted against subject age and are show shown in Figure 2.4.
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There was no significant correlation between cytokine expression and age (r values
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ranged between - 0.06 and+ 0.27). These results indicate that the difference in cytok.ine
expression between groups was not age-related. The low frequency of individuals
expressing IL-4 made age-specific comparisons meaningless in these study groups.
Since there were more females in the normal control group than in the autistic
group, the possibility of a gender-specific difference in cytokine expression was
examined by comparing the expression of IL-2 and interferon-y in males and females
within each study group and in the two groups as a whole. Student's t test indicated that
gender played no role in the expression of these cytokines (data not shown). The low
frequency of individuals expressing IL-4 made gender-specific comparisons meaningless
in these study groups.
DISCUSSION
The current study supports an association between autism and increased
expression of Th I-specific cytokines. A significant elevation of interferon-y and IL-2
mRNA levels and a higher frequency of individuals expressing interferon-y and IL-2
mRNAs was found in this study group of 24 autistic subjects. This indicates that there is
a Th1 type of immune response in many autistic individuals. At the same time, there was
almost no expression of IL-4 in the autistic group. This result argues against a Th2 type
of response in the autism.
The results reported here agree with conclusions drawn by Singh and associates
who used an ELISA-based method of cytokine analysis and found increased levels of IL2 and IL-12 in autistic individuals (Singh et al., 1991; Singh, 1996). Like IL-2, IL-12 is

an indicator of a Th 1 response. Our and Singh' s results contrast with those of Gupta et
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al. ( 1998), who reported a Th2 response in autistic individuals. Differences exist between
all these studies and include: 1) Gupta and associates' use of fresh rather than
cryopreserved PBMC; 2) the younger age of study subjects investigated by Gupta and
associates; and 3) the use of different methods (RT-PCR, ELISA and flow cytometry) to
assess cytokine production. It is unlikely that the use of cryopreserved rather than fresh
cells account for the different results because cryopreservation of PBMC has been
reported not to affect cell activation markers, viability, T cell function, preferential
stimulation of CD4+ vs. CD8+ T cells (van Lunzen et al., 1995), or the repertoire of T
cell receptors p chains (see Appendix A). Difference in the subject age also does not
appear to be an important factor leading to the different results of these studies as we
showed that cytokine mRNA expression and age were not related (Figure 2.4).
Examining cytokine levels in a single study group using the varied methods of all these
investigations may clarify the reasons for the different conclusions. Moreover, a long
term study from early childhood to adulthood would illuminate whether there is a stage
specific switch in the Th 1-Th2 response observed in autism.
Our results extend a growing body of observations that relate abnormal immune
functions to autism. Altered helper T cell function has also been reported in other
pediatric psychiatric diseases, including childhood-onset schizophrenia, obsessive
compulsive disorder and attention deficit hyperactivity disorder (Mittleman et al., 1997).
One possible mechanism linking Thi CD4+ T-cell activation in the peripheral blood and
autism is the ability of helper T cells to cross the blood-brain barrier (Wekerle et al.,
1986, 1994). Once within the central nervous system these cells could trigger an

inflammatory response that may damage areas of the brain critical to the development
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of autism. Although the work reported here does not allow drawing the conclusion that a
causal link exists between the Th1 immune response and autism, the repeated association
between autism and immune system abnormalities demands closer examination of this
central question.
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PREFERENTIAL EXPRESSION OF THE T CELL RECEPTOR
V-f3 CHAIN SUBTYPE V-f3 13 IN AUTISM
ABSTRACT
T cell-mediated immune abnormalities are associated with autism. The possibility
that specific T cell clones are expanded in autism was investigated in this work by
analyzing the expression of the 24 major T cell receptor (TCR)V-f3 chains in a group of
11 autistic and 9 normal subjects. The expression of theseV-f3 chains serves as a marker
for T cell clone expansion. Our results indicated that autistic subjects predominantly
expressedV-f3 13. The difference inV-f3 13 expression relative to the control group was
significant (p < 0.01; Wilcoxon's rank sum test). The expression ofV-f3 13 was especially
prevalent in the subgroup of autistic individuals who carried the DR4 or DRl alleles that
are common in autism.V-f3 19 and 22 are underrepresented (p < 0.01 and p < 0.05,
respectively) in the autistic group relative to the controls. This is the first report of an
alteration of the TCR repertoire in autism and is consistent with many previous reports that
immune system abnormalities are involved in autism. The prevalence of expandedV-f3 13expressing T cell clones strengthens evidence that at least some cases of autism are a result
of an autoimmune disorder.

INTRODUCTION
Multiple causes have been postulated for the etiology of autism, including genetic
factors, immune dysfunction (Warren et al., 1986), and viral infections (Chess, 1977;

Deykin and Macmahon, 1979; Markowitz, 1983). Immune abnormalities, especially T
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cell-mediated dysfunction, have been intensively investigated in autism. Relevant
findings associated with autism include increased serum levels of interleukin type 2 (IL2), interleukin type 12 (IL-12) and interferon-y (Singh, 1996), decreased T cell responses
to mitogens (Stubbs et al., 1977), depressed CD4+ T cell functions (Yonk et al., 1990),
decreased natural killer functions (Warren et al., 1990), and increased expression of the
DR+ surface marker (Warren et al., 1990; Plioplys et al., 1994).
T cell clone expansion is a hallmark of autoimmune diseases. A panel of these
documented autoimmune diseases with T cell clone expansion includes multiple sclerosis
(Wucherpfennig and Hatler, 1995; Lozeron et al., 1998), type I diabetes (Atlan-Gepner et

al., 1997), systemic lupus erythematosus (Furukawa et al., 1996; Holbrook et al., 1996;
Mato et al., 1997), Kawasaki disease (Abe et al., 1993), sarcoidosis (Moller et al., 1988),
microscopic polyarteritis (Simpson et al., 1995), and rheumatoid arthritis (Jenkins et al.,
1996; Davey and Munkirs, 1993). In every one of these disorders, one or a few T cell
clones form the predominant activated T cell population. Many other diseases, including
autism, are suspected to have an autoimmune basis and show T cell clone expansion.
Expanded T cell clones usually are identified on the basis of the T cell receptors
they express. The common T cell receptor is a heterodimer of a and p chains. The
specificity of antigen interaction with the TCR is controlled largely by the variable region
(V) of the p chain (Wucherpfennig and Hatler, 1995). Characteristic patterns of T-cell V
P expression have been associated with autoimmune diseases (McMurray et al., 1996).
Two methods are available for the detection of specific V-P chains: flow cytometry and

reverse transcription-based polymerase chain reaction (RT-PCR). RT-PCR has the
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advantage of greater sensitivity (Than et al., 1997) and now is the method of choice.
The studies reported here use RT-PCR of mRNA isolated from peripheral blood
to learn if particular T cells clones are expanded in autism. The expression patterns of the
24 major V-P chains were examined in a group of 11 autistic and 9 normal individuals.
V-P 13 was the predominant V-P chain expressed by autistic individuals, indicating the
expansion of a subset of T cell clones in many cases of autism. The association between
V-P 13 expression and autism was even more pronounced when the subgroups of
individuals who were positive for the antigen-presenting DR alleles that are associated
with autism (DR4 or ORI) were analyzed separately. The expansion ofV-p 13-expressing
T cell clones in autistic patients provides further evidence that at least some cases of autism
are a result of an autoimmune disorder.
MATERIALS AND METHODS
Study Subjects

This study examined 11 autistic and 9 normal subjects whose gender, age and DR
types of the study subjects are summarized in Table 3.1. The 11 autistic subjects were all
male with a mean age of 11.5 years and the diagnosis of autism was accomplished by
psychiatrists according to criteria for autism of the American Psychiatric Association
(1994). The male to female ratio of autistic individuals in the general population is about
4: 1 (Shaner, 1997). Seven autistic subjects had the human leukocyte antigen (HLA)
alleles DR4 or DRl that increase susceptibility to autism. The normal subjects (6 male, 3

Table 3.1
Sex,Age and DR Types of the Subjects for V-P Analysis
Normal

Autistic
Subject

a

Sex Age DR types

a

Subject

Sex

Age

DR types

#1

M

6

3,4

#1

M

8

9,12

#2

M

10

1,4

#2

F

10

3,4

#3

M

10

4,15

#3

F

10

l,7

#4

M

10

4,7

#4

M

10

3,13

#5

M

11

1,11

#5

M

11

4,12

#6

M

11

3,10

#6

F

12

l,15

#7

M

13

4,13

#7

M

13

11,12

#8

M

13

3,10

#8

M

14

4,15

#9

M

14

12,13

#9

M

15

7,9

#10

M

14

7,16

#11

M

15

4, 13

�umbers represent HLA DR types in short format where 1 = DRl,
3 = DR3,4 = DR4, etc.

female) had a mean age of 11.4 years. Five of these normal subjects had either the DR4
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or OR I allele. Child psychiatrists diagnosed autism according to diagnostic parameters of
American Psychiatric Association (1994).
HLA Typing
Blood was collected into heparin-coated tubes and peripheral blood mononuclear
cells (PBMC) were isolated by histopaque centrifugation. HLA typing was performed by
the microlymphocytotoxicity assay using a kit from One Lambda, Inc. (Canoga Park,
CA).
Total RNA Isolation and cDNA Synthesis
PBMC isolated by Ficoll-Hypaque centrifugation were stimulated with
phytohemagglutinin (PHA) (10 µg/ml) (Gibco, BRL). The cells were cultured in the
presence of PHA at 3 7°C in a humidified 5% CO2 atmosphere for 5 days before
extraction of total RNA. RNA was extracted from 5 x 10 5 PBMC using a kit according to
manufacturer's instructions (Trizol reagent kit, Gibco, Gaitherburg, MD). The resulting
total RNA was dissolved in 30 µl of sterile H2O and its concentration was determined by
absorbance at OD 260nm·
To synthesize cDNA, 2 µg of total RNA was reverse-transcribed using a kit
according to manufacturer's instructions (Boehringer, Mannheim, GmbH, Germany). The
20-µl reaction contained 0.1 OD26o of random hexamers, 40 units of RNase inhibitor, I
mM of each dNTP, 50 mM Tris (pH 8.3), 75 mM KCI, 3 mM MgCh, IO mM DTI, and
200 units of Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega,

Madison, WI). The mixture was incubated at 37°C for 2 hours.
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Precautions were taken to avoid mRNA degradation and contamination. cDNA
synthesis was always performed immediately following RNA isolation to minimize
potential for mRNA degradation. An RNase inhibitor (Promega, Madison, WI) was also
added at 1 unit/µl to the cDNA synthesis reaction. Solutions, glassware, pipets, and bench
surfaces were treated with diethyl pyrocarbonate to inactivate RNases.

TCR V-[J Chain Expression
The cDNA resulting from reverse transcription was divided equally into 24 tubes,
each containing a 5' TCR V-p-specific sense primer, a common 3' primer that annealed to
the constant region of the p chain, and 0.1 pg of competitor cDNAs. The competitor
cDNAs were kindly provided by Dr. D. Spinella (Chugai Biopharmacetics, San Diego,
CA) and served as internal controls of primer efficiency (Spinella and Robertson, 1994).
The 24 competitor cDNAs were constructed by inserting an 86-bp Xho II fragment from
pUC 19 into a unique Bgl II site in the constant region of the p chain.
PCR was performed in a 15-µl reaction that contained 10 mM Tris (pH 8.3), 50
mM KCI, 1.2 mM MgCb, 1 mM of each dNTP, 1 unit Taq DNA polymerase (Fisher
Scientific, Pittsburgh, PA), and 45 pmol of each primer. PCR was carried out with an initial
5 minutes of denaturation at 94 °C, followed by 30 cycles of the profile: l minute at 94 °C,
1 minute at 58 °C, and 1 minute at 72 °C. After the PCR, 4 µI of the reaction was analyzed
by electrophoresis through a 2% agarose gel. The gel was stained with ethidium bromide
and photographed under UV light, and the intensity of each band in the photograph was
quantified using Biosoft Image System (Biosoft, Ferguson, MO).

The relative expression of each V-P chain was determined according to
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Spinella and Robertson (1994). A value of 1.0 was assigned to the most intense
competitor band obtained in the 24 PCR reactions run from a single individual and all
other 23 competitor bands were normalized relative to this intensity value. These ratios
represent the amplification efficiency of the 24 primer pairs. Next, the intensity of the
endogenous V-P chain cDNA product was divided by the amplification efficiency of the
primer pair. These 24 values are referred to as corrected expression. Corrected expression
values were normalized relative to the highest corrected expression value in the set of 24
V-P chains. Each normalized value is referred to as a relative expression index (REI) and
provides an estimate of the relative amount of each V-P chain mRNA expressed in an
individual. Negative controls lacking template DNA were included in all PCR analyses.
In no case was there evidence of spurious amplification.
Wilcoxon's rank sum test (Harnett, 1982) was applied to estimate the significance
of differences in the rank order of V-P chain expression between the autistic and normal
groups.
Cytokine Expression
Interferon-y and interleukin type 4 (IL-4) mRNA levels were determined using
kits supplied by Clontech (Palo Alto, CA). Two µl of cDNA synthesized from PBMC
mRNA was placed into five tubes. Each tube contained a cytokine-specific primer pair
and 2 µl of a member of a 1 :3 dilution series of competitor cDNA. Five independent
reactions were performed using conditions described above for each subject for each
cytokine (see Chapter 2). The IL-2 mRNA levels were measured relative to actin mRNA

according the method ofHaraguchi et al. ( 1995). Actin mRNA expression was
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assumed to be constitutive. Separate PCRs were performed to amplify IL-2 and actin.
The PCR products were analyzed by electrophoresis through a 1.5% agarose gel and
photographed under UV light. The amount ofIL-4 and interferon-y mRNA was
determined by finding a lane in which the intensities ofthe competitor and endogenous
cDNA products matched. This occurred when the amounts ofstarting competitor and
endogenous cDNA were equal. Since there was a known amount ofcompetitor cDNA
added to each reaction, this gave the amount ofstarting endogenous cDNA. Relative
expression levels ofIL-2 were determined by comparison between the intensity ofthe
amplification products ofthe IL-2 and actin mRNAs from the same individual. This ratio
was termed arbitrary optical density units (AODU). Student's t test was used to analyze
the significance of differences between the average AODU in the autistic and normal
groups.

RESULTS
Competitive RT-PCR was used to study TCR V-p expression in autistic subjects.
Figure 3.1 shows a representative gel displaying RT-PCR products ofTCR V-p chain
mRNA from a autistic subject. Two DNA bands are visible in each lane ofthe gel (Figure
3.1 ). The smaller band is generated from target cDNA and the larger one is derived from
competitor cDNA. As expected, the products from competitor cDNAs were 86-bp larger
than the corresponding products ofendogenous mRNAs. The REI values for each V-P
derived from analysis ofthis gel are shown in Figure 3.2. V-P 3 and V-P 13 are the
predominant V-P forms expressed in this individual. This indicates that there was an
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Fig. 3.1. RT-PCR analysis of V-� chain expression in a single individual.
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expansion of T cells clones that express these forms ofthe TCR p chain in this
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individual. Similar analyses were performed for all subjects ofthe study.
The mean REI for each V-P chain was calculated in the autistic and normal groups.
These values were compared between the groups and are shown in Table 3.2. Inspection of
the results shows that in the autistic group V-P 13 was found at appreciably higher
frequency and V-P 14, 15 , 19 , and 22 were found at appreciably lower frequencies. The
significance of these differences was analyzed by Wilcoxon's rank sum test, a statistical
test that compares the rank order ofV-P chain expression between the two groups,
according to the methods of Jenkins et al. (1996). As shown in Table 3.2 , there was a
significant increase ofV-p 13 expression (p < 0.01) and a significant decrease in V-p 19 (p
< 0.0 l) and V-p 22 (p < 0.05) in the autistic subjects. Differences in the relative expression
of other V-p chains between groups were not significant according to this measure.
Individuals who possess either the DR4 or ORI allele are at greater risk of
developing autism (Warren et al., 1992). This led us to examine whether V-P chain
expression patterns would differ between the subgroups of autistic and normal subjects
who express either DR4 or ORI. Application of Wilcoxon's rank test showed that there
was significantly increased expression ofV-p 13 in autistic subjects (n = 7; p < 0.01)
relative to normal subjects (n = 5) with the mear.i REI of0.86 for V-p 13 in the autistic
group and 0.15 in the normal group. In this comparison of subgroups of DR4 or ORI
positive individuals, there was no significant difference in the relative expression ofV-p 19
and 22 as seen in the comparison of all autistic and normal individual s (Table 3.3). These
results showing significant expansion ofV-P expressing T cells clones in autistic
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Table 3.2
TCR V-P Expression in Autistic and Normal Subjects
V-P

Autistic (n = 11)
REia (µ±S.D.'J

Nonna! (n = 9)
REI\µ± s.o.'J

1
2
3
4
5
6
7
8
9
10
11
12

0.18±0.18
0.27±0.18
0.33±0.33
0.06±0.06
0.31±0.28
0.47±0.31
0.18±0.13
0.31±0.29
0.23±0.28
0.08±0.08
0.11±0.15
0.10±0.11

0.19±0.18
0.30± 0.34
0.33 ±0.41
0.14±0.32
0.33± 0.39
0.32±0.24
0.19±0.16
0.32±0.32
0.21±0.22
0.08±0.12
0.07±0.09
0.08±0.07

13

0.92 ± 0.17

0.34 ± 0.39

14
15
16
17

0.12±0.12
0.07±0.09
0.17±0.19
0.12±0.12
0.08±0.09

0.29±0.28
0.24±0.32
0.06±0.06
0.18±0.31
0.06±0.06

19

0.02 ± 0.03

20
21

0.08±0.14
0.33±0.28

22

0.06 ± 0.08

23
24

0.22±0.23
0.05±0.05

18

3

Wilcoxon's
Rank Sum Test

p< 0.0l

c

0.06 ± 0.06

p< 0.0l

c

0.15±0.16
0.29±0.26
0.25 ± 0.22
0.21±0.23
0.08±0.14

p< o.os

c

Relative expression index.
bMean± standard deviation.
cOnly values that indicate a significant difference between group
are shown.
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Table 3.3
TCR V-P Expression in Autistic and Normal Subjects Expressing DR4 or DRl
V-P
2
3
4
5
6
7
8
9
10
11
12
13

14
15
16
17
18

19
20
21
22
23
24

Autistic (n = 7)
REi a (µ± S.D.b)

Normal (n = 5)
REia (µ± S.D.�

0.19±0.22
0.24±0.22
0.31±0.39
0.07±0.08
0.26±0.31
0.50±0.36
0.17±0.16
0.34±0.37
0.26±0.35
0.09±0.09
0.15±0.18
0.12±0.14
0.86±0.20c
0.11±0.13
0.09±0.10
0.19±0.23
0.13±0.12
0.09±0.10
0.03±0.04
0.11±0.17
0.37±0.34
0.09±0.09
0.30±0.25
0.06±0.06

0.16±0.18
0.36± 0.40
0.34±0.41
0.22± 0.44
0.26±0.42
0.28± 0.25
0.15±0.13
0.35±0.35
0.15±0.16
0.06±0.08
0.05±0.06
0.07±0.05
0.15± 0.15c
0.23± 0.21
0.26± 0.42
0.03±0.03
0.04±0.02
0.06±0.06
0.05± 0.04
0.12± 0.16
0.15± 0.11
0.26±0.22
0.14±0.10
0.03± 0.04

aRelative expression index.
bMean±standard deviation.
cHighly significant difference (p < 0.01; Wilcoxon's rank sum test).

individuals correlate well with a previous finding that showed activation ofThl cells
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in the disease (see Chapter 2).
Six of the autistic subjects in this study were coparticipants in the study that
examined the profiles of IL-2, interferon-y and IL-4 expression as markers for activation
ofThl orTh2 cells (Chapter 2). A cross-study comparison was made using this group of
autistic subjects to learn if the correlation between the expansion of V-P 13-expresssingT
cell clones and elevated expression ofThl -specific cytokines (interferon-y and IL-2)
occurred in the same individuals.The relative expression level of V-P 13 was
significantly higher in this group of autistic individuals (n = 6) (seeTable 3.4) but not in
the normal controls (n = 9). As shown inTable 3.4, levels of theTh I-specific cytokines
IL-2 and interferon-y are also elevated in the same group of autistic individuals.This
correlation of expansion of V-P 13-expresssingT cell clones and elevated expression of
IL-2 and interferon-y in the same set 0f autistic individuals suggests that both these
processes may cooperatively interact in the pathogenesis of autism.
DISCUSSION
In this study, we showed that in many autistic individuals elevated V-p 13 chain
expression is elevated.This is the first report of an alteration of theTCR repertoire
associated with autism.This finding is consistent with many previous reports of altered
immune responses in autism. Expression of particularT cell clones occurs in many
autoimmune diseases (Marchalonis et al., 1994; Schneider and Gronvik, 1995; Wooley
and Cingel, 1995), and our finding of V-P 13 expansion in autism provides evidence that at
least some cases of autism are a result of autoimmunity.

Table 3.4
Cytokine and V-P Chain Expression in Six Autistic Subjects
DR

Age
(years) IL-2/Actin a

Interferon-y mRNA Molecules

V-P 13

per µg of Total RNA

(REI'J

19,293
N.D.c

1.00

Group

Subject

Sex

Types

Autistic

#1

M

19

0.85

#2

M

4, 7
I, 4

9

0.42

#3
#4
#5
#6

M
M
M
M

12, 13
1, 11
3, 10
4, 13

15
11
11
13

0.31
0.65
1.33
0.05

N.D.c
19,293
519,280
19,293

0.58±0.45

15,900 ± 15,900

0.88±0.20

(n = 6)

{n = 6)

d

Autistic subjects (µ± SD )

(n
d

=

6)

1.00
0.50
1.00
1.00
0.80

Normal subjects (µ± SD )

0.18±0.20
(n = 19)

4,500± 8,200
(n = 19)

0.34 ± 0.39
(n = 11)

Student's t test

p < 0.01

p < 0.01

p < 0.01

a

IL-2 mRNA levels relative to actin mRNA levels.

bRelative expression index.
�ot detectable in the assay.
d

Mean±standard deviation.
-....}
I.H

The TCR repertoire is determined by many factors, including genetic factors,
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major histocompatibility complex (MHC)-mediated selection by antigens during T cell
development in the thymus, and by infection (Islam et al., 1996). TCR repertoires are
significantly altered in many autoimmune disorders (Marchalonis et al., 1994; Schneider
and Gronvik, 1995; Wooley and Cingel, 1995). For example, in rheumatoid arthritis, V-13
17 expression predominates (Davey and Munkirs, 1993; Fischer et al., 1996), and in
multiple sclerosis T cell clones that express V-13 8 predominant (Wucherpfennig and
Hafter, 1995). It is tempting to speculate that a similar link exists between the expansion
of V-13 13-expressing T cell clones and the development of autism.
The expression of V-13 13 was especially prevalent in the group of autistic
individuals who carried the DR4 or DRl alleles that are common in autism. In many
autoimmune diseases, including insulin-dependent diabetes mellitus, rheumatoid arthritis,
and multiple sclerosis, there is a strong association between the disease and the
expression of a particular DR molecule (Geha et al., 1994). These autoimmune diseases
also show preferential expression of particular V-13 chains that indicate expansion of
specific T cell clones (Grunewald et al., 1998; Navaneetham et al., 1998; McKee et al.,
1999). One model that links these observations postulates that specific DR molecules
present some antigens in a way that is recognized preferentially by a single form of TCR.
If the DR-antigen complex mimics a self-antigen, the T cell clone that is expanded by
stimulation with a foreign antigen could produce an autoimmune response that targets
host tissue specific to the disease. This may be the case in the relationship between DR4
or DRl and V-p 13-expressing T cells in autism.
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There is a correlation between dominant expression of V-p 13 and the expression
of Thl-specific cytokines IL-2 and interferon-yin the 6 autistic individuals who
participated in this study and an earlier investigation of cytokine expression study (Chapter
2). Enhanced cytokine expression and expansion ofT cells that express V-P 13 may be tied
together in a positive feedback loop in which the cytokines stimulateT cell proliferation
and in turn theT cells produce yet more Thl specific cytokines. IfV-P 13-expressingT
cells are involved in an autoimmune response in autism, elevated cytokine expression is
likely to exacerbate symptoms of the disease.
The identification of V-P 13 as the predominant V-P chain expressed in most
autistic individuals may aid in the identification of autoantigens that are targeted in the
disease. One approach to this goal would be to isolate the V-p 13-expressingT cell clones
from autistic patients and test their ability to be stimulated by self-antigens.
If the finding of an association between autism and expansion ofT cell clones
expressing V-P 13 is general, then there is the possibility for immune therapy based on
deletion of these specific T cell clones. Such an approach has been successfully
demonstrated in animal models of multiple sclerosis, where treatment with antibody
directed against the predominant TCR V-P 8 chain dramatically reduced mortality
associated with the disease (Gold et al., 1997; Vandenbark et al., 1992).
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INVESTIGATION OFT CELL RESPONSE TO EPITOPES OF
SUSPECTED PATHOGENS IN AUTISTIC PATIENTS
ABSTRACT
This communication reports tests of two models for autism that are based on T
cell-mediated immune abnormalities. One model postulates that infections in
compromised individuals allow pathogen persistence to cause central nervous system
(CNS) damage that leads to autism. A prediction of this model is that autistic individuals
will show a reduced immune response to the pathogen that triggered the disease. T cell
epitopes derived from pathogens suspected to cause autism were examined for their
ability to induce T cell proliferation in autistic and normal subjects. As a group, the T
cells of autistic subjects did not show an altered response to peptides derived from rubella
virus, herpes simplex virus type 1 (HSV-1), cytomegalovirus (CMV), Epstein-Barr virus
(EBV), and Clostridium tetani. Increased T cell proliferation in autistic individuals to a
peptide derived from influenza A virus was noted. These results do not support a model
in which autism is caused by an immune tolerant response to any of the pathogens tested
here. Another model of autism tested here is that autism is induced by pathogens that
possess epitopes identical to the hypervariable region 3 (HVR-3) of the human leukocyte
antigen (HLA) DR4 or DRl alleles that are prevalent in autism. This model proposes that
T cell-mediated immunity is ineffective against these pathogens so they persist and
ultimately cause CNS damage that produce autism. Peptides derived from the
Escherichia coli (E. coli) dna J and the Epstein-Barr virus (EBV) glycoprotein (gp) 110

that contain sequences identical to the HVR-3 of the DR4 and DRl alleles were
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examined for their ability to induce T cell proliferation in DR4 or DRl positive and
negative autistic and normal subjects. There was no relationship between possession of
DR4 or DRl allele and the ability to respond to either peptide. Although the results of
these studies do not provide support for involvement of a specific pathogen in autism, the
average T cell proliferative activity of autistic subjects was lower than that of normal
individuals. This result is consistent with prior reports that show there is a reduced T cell
mediated immune response in autism.
INTRODUCTION
Infections have long been associated with autism (Chess, 1977; Stubbs, 1976),
although the mechanism that couples infections with the development of autism is
unknown. Pathogens associated with autism by epidemiological investigations mainly
include rubella virus, HSV-1, and CMV. In addition, immunization with rubella and
tetanus vaccines has been proposed to cause autism in a small number of individuals
(Munyer et al., 1975; Rossier et al., 1977). A potential link between infection and autism
is the depression of immune functions that is often seen in autistic subjects. These
reduced immune system functions include lower numbers of CD4+ T cells (Yonk et al.,
1990; Warren et al., 1990), decreased amounts of complement C4B (Warren et al., 1995),
reduced responsiveness to mitogens (Yonk et al., 1990; Warren et al., 1986), depressed
functions of natural killer cells (Warren et al., 1987), and abnormal cytokine profiles
(Singh et al., 1991; Singh, 1996; Gupta et al., 1998) indicative of defective T cell
functions. One model that relates infection and autism postulates that if pre- or postnatal

infections occur in individuals with a reduced ability to clear the infectious agent, this
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will allow the pathogen to persist and cause CNS damage that leads to autism. One
prediction of this model is that autistic individuals will show a reduced T cell-mediated
immune response to the pathogen that triggered the disease. This prediction was tested
here by assessing the T cell proliferation responses of autistic and normal subjects to a set
of peptide epitopes derived from pathogens suspected to cause the disease.
HLA DR molecule-mediated autoimmunity may be involved in some cases of
autism. For this reason, another model of autism is based on understanding of the
autoimmune disorder rheumatoid arthritis (RA) and the roles played by specific HLA DR
alleles. HLA DR molecules are T cell surface proteins involved in antigen presentation
(Geha et al., 1994; Auger et al., 1996). In both RA and autism, individuals who possess
either the HLA DR4 or DRl allele are susceptible to the diseases (Albani et al., 1992a;
Warren et al., 1992; Daniels et al., 1995). DR proteins contain a set of allele-specific
sequences known as hypervariable regions that have key roles in antigen binding and
presentation, with the third hypervariable region (HVR-3) exerting a predominant effect
(Geha et al., 1994). In RA, it is postulated that pathogens that display antigens with
regions similar to the HVR-3 induce immune tolerance (Salvat et al., 1994). It is well
noted that the E. coli dna J protein and EBV gpl 10 possessed a sequence identical to the
core pentapeptide sequence (QKRAA) of the HVR-3 of HLA DR4 and DRl (Albani et
al., 1992b). These E. coli dna J and EBV gpl 10 proteins appear to be important antigenic
determinants associated with RA as a high titer of antibodies directed against them is
found in the synovial fluid of RA patients (Takeuchi et al., 1990). Moreover, dna J and
gp110 act as potent inducers of T cell proliferation in both in vitro and in vivo assays

(Ikeda et al., 1996; Roudier et al., 1988, 1989). When DR4- or DRI-positive RA
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patients were tested for their T cell proliferative responses induced by peptides derived
from the E. coli dna J protein and EBV gpl 10 that contained the QKRAA sequence,
there was a significantly reduced response relative to RA patients and normal controls
who expressed other DR alleles (Salvat et al., 1994). Based on these results, Salvat and
his coworkers proposed that some cases of RA may be caused by infections with EBV or

E. coli that are ineffectively cleared in HLA DR4- or ORI-positive individuals (Salvat et
al., 1994). Given the parallel between possession of HLA DR4 and ORI and
susceptibility to RA and autism, we explored the possibility that DR4- or ORI-positive
autistic individuals would show a reduced T cell proliferative response to dna J and
gp110 peptides that contain the QKRAA sequence. This communication reports the
results of tests of both models of autism.
MATERIALS AND METHODS
Synthesis of T-Cell-Epitope-Derived
Peptides
Ten peptides that represent the major T cell epitopes of pathogens suspected in
the etiology of autism were synthesized and purified by high performance liquid
chromatograph at the Utah State University Biotechnology Center. Table 4.1 lists the
amino acid sequences of these peptides.
Subjects Studied
The sex, age, and HLA DR types of the 24 autistic and 18 normal subjects
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Table 4.1
Peptides Used in the T Cell Proliferation Assay
a

Peptide

Sequence

Rubella capsid (9-29)

MEDLQKALEAQSRALRAELAA

Rubella El (262-283)

DPLLRTAPGPGEVWTPVIGSQ

Rubella E2 (51-75)
HSV gC-1 (128-140)
HSV gD-1 (5-23)

YRNASDVLPGHWLQEEWGCYN
NRRDPLARYGSRC
ADASLKMADPNRFRGKDLP

CMV gB (618-628)

FIAGNSAYEYV

Influenza M (58-66}

GILGFVFTL

Tetanus toxin (947-968 )
EBV gp110 (803-818)

E. coli dna J (56-75)

FNNFTVSFWLRVPKVSASHLEG
b
EQNQEOKRAA QRAAGC

VLTDSQKRAAbYDQYGHAAF

�umbers in parantheses indicate the amino acid position in the proteins
b

The underlined sequences indicate the amino acid sequence shared with

the HVR-3 region of HLA types DR4 and DRl.

included in this study are shown in Table 4.2. The diagnosis of autism was
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accomplished by psychiatrists according to criteria for autism of the American
Psychiatric Association (1994). At the time of blood collection, there was no record that
any autistic or normal subject received medications, had concurrent medical conditions
that might affect the results of the study, or showed signs of infection or allergy. The
studies were approved by the Utah State University Human Subject Review Board and
written consent from study subjects or their parents was obtained.
T Cell Proliferation Assay
Peripheral blood mononuclear cells (PBMC) from fresh venous blood of each
subject were isolated by histopaque density centrifugation. In outline, the T cell
proliferation assay was based on previously published methods (Chain et al., 1987; Orlik
and Spiltter, 1996) that were optimized in this laboratory (see Appendix B). These final
conditions were used for all peptides in this study. For the assay, 5 x 106 PBMC freshly
isolated from the same subject were placed in triplicate wells of 96-well flat-bottomed
microculture plates (Cell Walls™, Corning, New York) and incubated at 37°C in a
humidified 5% CO2 atmosphere. Peptides at a final concentration of 1 µM were added
(see Appendix B). Triplicate negative controls without peptide addition were included in
all experiments. One day later, recombinant interleukin type 2 (IL-2) was added to a final
concentration of 30 international units/ml (Chiron, Emeryville, CA) (see Appendix B).
Five days after starting the assay, 2 µI of 3H-thymidine (1 µCi; Moravek Biochemicals.
Inc., Brea, CA) was added to each well. The cells were incubated 3 hours, then
transferred by vacuum filtration to a membrane using a cell transfer device (Micromate-

Table 4.2
Sex, Age and HLADR Types of the Study Subjects
Autistic
#1
#2
#3
#4
#5
#6
#7
#8
#9
#IO
#11
#12
#13
#14
#15
#16
#17
#18
#19
#20
#21
#22
#23
#24

Sex
M
M
M

F
M
M
M
F
M
M
M
M
F
F
M
F
M
M
M
M
M
M
M
M

Age
3
4
5
6
6
6
9
10
IO
11
11
12
13
14
16
16
17
19
20
23
25
26
27
39

HLADR
7,7
1,13
7,15
3,3
1,13
3,7
4,16
7,13
7,13
I,15
7,7
I,8
4,4
3,4
4,15
1,4
1,7
4,15
4,7
4,4
1,7
4,15
1,7
4,15

Normal
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
#15
#16
#17
#18

Sex
M
F
M
M
M
M
F
M
M
M
M
F
M
M
M
M
M
M

Age HLADR
7,7
3
4
4,7
5
11,13
8
7,7
8
1,3
8
7,11
9
13, 15
10
3, IO
14
11,14
15
11,13
15
4,8
4,7
16
16
13, 15
16
11,13
18
3, 13
18
1,13
29
13, 15
41
1,3

3

196, Packard Instrument Inc., Dower Grove, IL). Unincorporated H-thymidine was
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removed by washing cells on the membrane and the incorporated counts were determined
using a P-counter (Matrix™-96, Packard Instrument Inc., Dower Grove, IL). The average
counts per minute (cpm) for triplicate wells analyzed for each condition (10 peptides and
no peptide control) was calculated. A stimulation index (SI) for each peptide was
calculated as the ratio of the average cpm incorporated in the presence of peptide over the
average cpm of the no-peptide control in the same individual.
Statistical Analysis
The SI values were grouped into categories of positive response (SI> 1.95), no
response (1.95�SI�0.5), and negative response (SI< 0.5). The cutoffs of SI> 1.95 and
SI < 0.5 are according to Schrier et al. ( 1995). x2analysis was performed to examine the
significance of differences between the autistic and normal groups. The results were also
analyzed on the basis of absolute cpm incorporated in the T cell proliferation assay. In
this case, Student's t test was used.

RESULTS
Response to T-Ce/1 Epitopes of Pathogens
Implicated in Autism
PBMC obtained from a group of 24 autistic and 18 normal controls were
challenged with 8 synthetic T cell epitopes of 5 pathogens (rubella virus, HSV-1, CMV,
influenza A virus, and Clostridium tetani) that were implicated as potential causative
factors in autism (Deykin and Macmahon, 1979). The proteins used to derive the
synthetic T cell epitopes were the rubella virus caspid (C), envelop (E1), and envelop

(E2) (McCarthy et al., 1993), HSV-1 glycoprotein C-1 (gC-1) and glycoprotein D-1
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(gD-1) (Jayaraman et al., 1993), CMV glycoprotein B (gB) (Mayer et al., 1996), the
influenza A virus matrix (M) protein (Mayer et al., 1996), and the Clostridium tetani
toxin (Valmori et al., 1994), whose antigenecities are well demonstrated.
The T cell proliferation induced by each peptide in each subject was expressed as
SI, the ratio of 3H-thymidine incorporated by PBMC exposed to peptide relative to the
3H-thymidine incorporated by control cells not exposed to peptide. SI values ranged
widely for each peptide in both autistic and normal subjects. To facilitate comparisons
between the autistic and normal groups, the method of Schrier et al. (1995) was followed
in which SI values are classified into one of three categories: a positive response to the
peptide (SI> 1.95), no response to the peptide (1.95�SI�0.5), and a negative response
to the peptide (SI < 0.5). This simplification of results allowed testing of ranked T cell
proliferative response by x2 analysis.
The analysis of results for all eight peptides in autistic and normal subjects
indicated that there was no reduction in T cell proliferation induced by any peptide in the
autistic group (Table 4.3). The only difference between the autistic and normal groups
was an increased response to the influenza A virus M protein in the autistic group (Table
4.3)
The results of peptide challenge to PBMC of autistic and normal subjects were
also analyzed by comparing the mean cpm of the 3H-thymidine incorporated both in the
presence or absence of added peptides in the autistic and normal groups. As shown in
Table 4.4, for all peptides the PBMC of autistic subjects incorporate less 3H-thymidine
than the equivalent number of PBMC of normal subjects under identical assay conditions.

Table 4.3
Ranked T Cell Proliferation Response to Eight T Cell Epitop es
Autistic Subjects (n = 24 )
Peptide

Normal Subjects (n = 18)

a
Si > 1.98 1.95 2: Si a 2: 0.5 Si a < 0.5

a
Si > 1.98

a

1.95 2: Si 2: 0.5 Si a < 0.5

2

X

p value

Rubella capsid (9-29)

6

13

5

4

12

2

0.89

p > 0.05

Rubella El (262-283)

4

16

4

3

13

2

0.27

p > 0.05

Rubella E2 (51-75)

3

17

4

3

12

3

0.15

p > 0.05

HSV gC-1 (128-140)

7

14

3

3

13

2

1.00

p > 0.05

HSV gD-1 (5-23)

3

18

3

0

16

2

2.51

p > 0.05

CMV gB (618-628)

6

15

3

3

13

2

0.50

p > 0.05

Influenza A virus M (58-66)

5

13

6

0

16

2

6.59

p < 0.05

Tetanus toxin (947-968)

6

14

4

3

11

4

0.51

p > 0.05

aStimulation index.

'°
0

The difference between groups was significant according to Student's t test for all
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rubella- and HSY-derived peptides. The average 3H-thymidine incorporated by PBMC
not exposed to peptide in the autistic and normal groups was actually higher than that
observed following treatment with most peptides. This does not indicate that no
individuals showed a positive response to peptide exposure, only that on average neither
the autistic nor the normal group showed stimulation by peptides. This is consistent with
the analysis of this data set by SI values, which shows that roughly equal numbers of
individuals of each group respond positively or negatively to any peptide (Table 4.4).
Stimulation with the mitogen, phytohemagglutinin (PHA), was used as a positive
control to test the responsiveness of T cells in the PBMC preparations. For both the
control and autistic groups, PHA induced a strong response over background levels
observed in PBMC without any addition of mitogen (Table 4.4). As previously reported
(Stubbs et al., 1977; Warren eta/., 1986), the level of 3H-thymidine incorporation in
PHA-treated cells was lower in the autistic group relative to normal controls (Table 4.4).
However, in contrast to these earlier reports, this difference was not statistically
significant.
Responses to Peptides with Sequences
Similar to HLA DR4 or DRJ
T cell proliferation was examined in response to peptides of the E. coli dna J and
EBV glycoprotein (gp)l 10 protiens which contain the pentapeptide sequence QKRAA
that is present in the HVR-3 of HLA OR4 or ORI. The average SI value of the OR4- or
ORI-positive autistic subjects was compared with the SI value of three different groups:
OR4- or ORI-negative autistic individuals (n = 7), OR4- or DRI-postitive normal
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Table 4.4
H-Thymidine Incorporation after Exposure to 10 Peptides
in Normal and Autistic Subjects
Autistic (n = 24)

Normal (n = 18)

Student's t Test

µ±SD

p valueb

303 ±334

1109 ±1553

0.041

Rubella El (262-283)

253 ±265

801 ±832

0.011

Rubella E2 (51-75)

258 ±264

806 ±1111

0.049

HSV gC-1 (128-140)

297 ±278

957 ±1272

0.040

HSV gD-1 (5-23)

237 ±268

644 ±725

0.030

CMV gB (618-628)

479 ±965

938 ±1154

0.149

Influenza A virus M (58-66)

261 ±301

1009 ±1753

0.086

Tetanus toxin (947-968)

354 ±424

901 ±1408

0.107

PHA

3238 ±3669

4997 ±5971

0.228

Background

405 ±706

1054 ±1283

0.054

a

Peptide

µ±so

Rubella capsid (9-29)

a

a

Mean ±standard deviation.
bThe difference between the autistic and normal subjects was determined by Student's t
test.

individuals (n = 6), and DR4- or ORI-negative normal individuals (n = 12). There was
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no significant difference in the average SI values in any comparison (Table 4.5).
The ages of autistic subjects used in this study varied widely (3-39 years). Since
age is known to be a factor in the immune response, we investigated whether age played
a role in T cell responsiveness to peptides in the current study. Autistic subjects were
grouped into categories of prepubescent children and adults using a cutoff age of 14
years. The SI values observed in response to peptide exposure in these age groups are
shown (Table 4.6). There was no significant effect of age in response to peptide.
DISCUSSION
Two questions were examined in this study. The first was whether autistic
individuals have a compromised T cell-mediated immune response to pathogens reported
to be associated with the disease. The second was whether pathogens with T cell
epitopes similar to the T cell-interacting HVR-3 of HLA DR4 or DRl were tolerated in
autistic individuals. Both questions were tested by examining the T cell proliferation
responses of autistic and normal subjects to a set of peptide epitopes derived from
pathogens implicated in autism.
Averaged as a group, T cells of autistic subjects did not show a reduced
proliferative response to peptides derived from rubella virus, HSV-1, CMV, influenza A
virus, and Clostridium tetani. The only difference was an enhanced response to the
influenza A virus M protein in autistic subjects. Therefore, these results do not provide
support for the idea that a lower immune response to infections or immunization against
common viruses plays a significant role in the disease. However, in coming to this

Table 4.5
Proliferation Response to EBV gpl10 and E. coli. dna J Peptides8
Autistic Subjects with

Autistic Subjects without

Normal Subjects with

Normal Subjects without

DR4 or DRl (n = 17)
C
Si b (µ± SD )

DR4 or DRl (n = 7)
C
Si b (µ± SD )

DR4 or DRl (n = 6)
C
b
Si (µ± SD )

DR4 or DRI (n = 12)
b
C
Si (µ± SD )

EBV gpllO
(803-818)

1.10 ± 0.73

1.23 ± 1.16

1.75 ± 2.02

1.19 ± 0.65

E.coli dna J
(56-75)

1.79 ± 1.06

1.35 ± 1.55

2.90 ± 3.46

1.22 ± 0.66

Peptide

8

Student's t test indicated no significant difference in SI between the DR4 or DRl positive autistic individuals compared to

all other groups.
b
Stimulation index.
cMean ± standard deviation.

\,0

�
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Table 4.6
Proliferation Response to 10 Peptides in
8
Two Age Groups of Autistic Subjects
Age< 14
(n = 13)

Age� 14
(n = 11)

Peptide

C
Si b (µ±SD )

Si b (µ±SOC)

Rubella capsid (9-29)

1.30±1.05

1.82±1.28

Rubella El (262-283)

1.07±0.74

1.44±0.70

Rubella E2 (51-75)

1.12±0.68

1.51±0.76

HSV gC-1 (128-140)

1.58±1.38

1.44±0.65

HSV gD-1 (5-23)

1.11±0.95

1.27±0.85

CMV gB (618-628)

1.92±1.47

1.13±0.40

Influenza A virus M (58-66)

1.21±0.93

1.16±0.73

Tetanus toxin (947-968)

1.33±0.99

1.79±1.42

EBV gpl 10 (803-818)

1.11±0.91

0.96±0.54

E. coli dna J (56-75)

1.39±1.11

1.71±0.95

Student's t test indicated that there were no significant differences between
age groups in response to any peptide.
b
Stimulation index.
cMean±standard deviation.
8

conclusion, it is important to realize that widely varying individual responses were
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seen in each group. It remains possible, as suggested by epidemiological studies, that
some cases of autism are caused by infectious agents. If these cases occur at low
frequency, the method of comparison between groups that was used here would fail to
detect them.
The second hypothesis examined in this work was the possibility that autism may
be induced by pathogens that possess protein antigens that share sequences with theHLA
DR4 or DRl . These particular DR types are expressed at much higher frequencies in
autistic subjects than in the general population (Daniels et al., 1995; Warren et al., 1992).
We measured the ability of theHVR-3-like peptide epitopes (dna J from E. coli and
gp l 10 for EBV) to induce T cell proliferation in autistic and normal subjects. Both E. coli
dna J and EBV gp110 are significant antigens of each pathogen and dna J antibodies and
activated T cell clones have been reported in the synovial fluid of RA patients (Winfield,
1989; Albani et al., 1992a; Ikeda et al., 1996). Our results failed to provide support for
the hypothesis that DR4- or DRl-postitive autistic individuals are tolerant to the E. coli
and EBV peptides that share sequences with theHVR-3 ofHLA DR4 or DRl. The same
caveat holds in this study of the response toHLA DR4- and ORI-like peptides as for the
investigation of the response to pathogen -derived peptides: a comparison of group
averages will not detect a small number of cases of autism that result from immune
tolerance of E. coli or EBV in DR4- or ORI -positive subjects.
Although peptide-specific differences in T cell response between autistic and
normal subjects were not detected in this investigation, a striking finding was the
generally lowered T cell proliferation seen in autistic individuals. The analysis of

peptide-specific responses was made by comparisons of the SI. However, when the
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absolute amount of 3 H-thymidine incorporated in the assay is compared, the PBMC of
autistic individuals incorporated only about half the amount of 3H-thymidine with or
without peptide than PBMC of normal subjects. This difference could be due to reduced
T cell activity in autistic individuals as the same numbers of fresh PBMC (5

x

106) were

assayed in all individuals. It is likely that reduced T cell function would adversely affect
the immune capabilities of autistic subjects. A generally depressed immune response
using various measures has been reported frequently in autism (Warren et al., 1987,
1990, 1991; Yonk et al., 1990). This global depression in immune responsiveness,
whatever its cause, may play a more important role in autism than reduced
responsiveness to any one particular pathogen.
REFERENCES
Albani S., Carson D.A., and Roudier J. (1992a) Genetic and environmental factors in the
immune pathogenesis of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 18,
729-740.
Albani S., Tuckwell J.E., Esparza L., Carson D.A., and Roudier J. (1992b) The
susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope
shared by the Escherichia coli heat shock protein dna J and the
histocompatibility leukocyte antigen DRP 1-0401 molecule. Clin. Invest. 89, 327331.
American Psychiatric Association. (1994) Diagnostic and Statistical Manual ofMental
Disorders, 4th Edition, American Psychiatric Association, Washington, DC.

Auger I., Escola J.M., Gorvel J.P., and Roudier J. (1996) HLA-DR4 and HLA-DRl

98

motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock
proteins. Nat. Med. 2, 306-310.
Chain B., McCafferty I., Wallace G., and Askenase P.W. (1987) Improvement of the in
vitro T cell proliferation assay by a modified method that separates the antigen
recognition and IL-2-dependent steps. J lmmunol. Methods 99, 221-228.
Chess S. (1977) Follow-up report on autism in congenital rubella. J Autism Child.
Schizophr. 1, 68-81.
Daniels W.W., Warren R.P., Odell J.D., Maciulis A., Burger R.A., Warren W.L., and
Torres A. R. (1995) Increased frequency of the extended or ancestal haplotype
B44-SC30-DR in autism. Neuropsychiatry 32, 120-123.
Deykin E.Y. and Macmahon G. (1979) Viral exposure and autism. Am. J Epidemiol.
109, 628-638.
Geha R., Rose N.R., Sachs D.H., Sprent J., and Weiner H. (1994) in lmmunobiology
(Janeway C.A., and Traves P., eds.), pp. 11:15-18, Current Biology Ltd., Garland,
New York, NY.
Gupta S., Aggarwal S., Rashanravan B., and Lee T. (1998) Th l - and Th2-like cytokines
in CD4+ and CD8+ T cells in autism. J Neuroimmunol. 85, 106-109.
Ikeda Y., Masuko K., Nakai Y., Kato T., Hasanuma T., Yoshino S.I., Mizushima Y.,
Nishioka K., and Yamamoto K. (1996) High frequencies of identical T cell
clonotypes in synovial tissues of rheumatoid arthritis patients suggest the
occurrence of common antigen-driven immune responses. Arthritis Rheum. 39,
446-453.

Jayaraman S., Heiligenhaus A., Rodriguez A., Soukiasian S., Dorf M.E., and Foster

99

C.S. (1993) Exacerbation of murine herpes simplex virus-mediated stromal
keratitis by Th2 type T cells. J Immuno/. 151, 5777-5789.
Mayer S., Scheibenbogen C., Lee K.H., Keilholz W., Stevanovic S., Rammensee H.G.,
and Keilholz U. (1996) A sensitive proliferation assay to determine the specific T
cell response against HLA-A2.l-binding peptides. J Immuno/. Methods 197, 131137.
McCarthy M., Lovett A., Kerman R.H., Overstreet A., and Wolinsky J.S. (1993)
Immunodominant T-cell epitopes of rubella virus structural proteins defined by
synthetic peptides. J Viral. 67, 673-681.
Munyer T.P., Mangi R.J., Dolan T., and Kantor F.S. (1975) Depressed lymphocyte
function after measles-mumps-rubella vaccination. J Infect. Dis. 132, 75-78.
Orlik 0. and Splitter G.A. (1996) Optimization of lymphocyte proliferation assay for
cells with high spontaneous proliferation in vitro: CD4+ T cell proliferation in
bovine leukemia virus infected animals with persistent lymphocytosis. J
Jmmuno/. Methods 199, 159-165.
Rossier E., Phipps P.H., Polley J.R., and Webb T. (1977) Absence of cell-mediated
immunity to rubella virus 5 years after rubella vaccination. Can. Med. Assoc. J

116, 481-484.
Roudiet J., Petersen J., Rhodes G.H., Luka J., and Carson D.A. (1989) Susceptibility to
rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR P-1
chain and the Epstein-Barr virus glycoprotein gpl10. Proc. Natl. Acad. Sci. USA
86, 5104-5108.

Roudier J., Rhodes G., Petersen J., Vaughan J.H., and Carson D.A. (1988) The

100

Epstein-Barr virus glycoprotein gpl 10, a molecular link between HLA DR4, HLA
DRl, and rheumatoid arthritis. Scand. J lmmunol. 21, 367-371.
Salvat S., Auger I., Rochelle L., Begovich A., Geburher L., Sette A., and Roudier J.
(1994) Tolerance to a self-peptide from the third hypervariable region of the
HLA-DR-1 *0401 in rheumatois arthritis patients and normal subjects. J
lmmunol. 153, 5321-5329.
Schrier R.D., Freeman W.R., Wiley C.A., and McCutchan (1995) J.A. Immune
predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group. C/in.
Invest. 95, 1741-1746.
Singh V. (1996) Plasma increase of interleukin-12 and interferon-y pathological
significance in autism. J Neuroimmunol. 66, 143-145.
Singh V.K., Warren R.P., Odell J.D., and Cole P. (1991) Changes of soluble interleukin2, interleukin-2-receptor, T8 antigen and interleukin-I in the serum of autistic
children. C/in. lmmuno/. lmmunopathol. 61, 448-455.
Stubbs E.G. (1976) Autistic children exhibits undetectable hemagglutination-inhibition
antibody titers despite previous rubella vaccination. J Autism Child. Schizophr. 6,
269-274.
Stubbs E.G., Crawford M.L., Burger D.R., and Vanderbark A.A. (1977) Depressed
lymphocyte responsiveness in autistic children. J Autism Child. Schizophr. 1, 4955.
Takeuchi F., Kosuge E., Matsuta K., Nakano K., Tokunaga K., Juji T., and Miyamoto
T. (1990) Antibody to a specific HLA-DR p 1 sequence in Japanese patients with

rheumatoid arthritis. Arthritis Rheum. 33, 1867-1868.

101

Valmori D., Sabbatini A., Lanzavecchia A., Corradin G., and Matricardi P.M. (1994)
Functional analysis of two tetanus toxin universal T cell epitopes in their
interaction with DRl 101 and ORI 104 alleles. J Immunol. 152, 2921-2929.
Warren R.P., Foster A., and Margaretten N.C. (1987) Reduced natural killer cell activity
in autism. J Am. Acad Child Adolesc. Psycho/. 26, 333-335.
Warren R.P., Margaretten N.C., Pace N.C., and Foster A., (1986) Immune abnormalities
in patients with autism. J Aut. Devel. Dis. 16, 189-197.
Warren R.P., Singh V.J., Cole P., Odell J.D., Pingree C., Warren W.L., Dewitt C.W., and
McCullough M. (1992) Possible association of the extended MHC haptotype
B44-SC30-DR4 with autism. Immunogenetics 36, 203-207.
Warren R.P., Singh V.K., Cole P., Odell J.D., Pingree C.B., Warren W.L., and White E.
(1991) Increased frequency of the null allele at the complement C4B. Clin. Exp.
Immunol. 83, 438-440.
Warren R.P., Yonk L.J., Burger R.A., Cole P., Odell J.D., Warren W.L., White E., and
Singh V.K. (1990) Deficiency of suppresor-inducer (CD4+ CD45 RA+) T cells in
autism. Immunol. Invest. 19, 245-252.
Warren R.P., Yonk J., Burger R.P., and Odell D. (1995) DR-positive T cells in autism:
association with decreased plasma levels of the complement C4B protein.
Neuropsychobiol. 31, 53-57.
Winfield J.B. (1989) Stress proteins, arthritis, and autoimmunity. Arthritis Rheum. 32,
1497-1504.
Yonk L.J., Warren R.P., Burger R.A., Cole P., Odell D., Warren W.L., White E., and

Singh V.K. (1990) CD4+ helper T cell depression in autism. Immunol. Lett.
25, 341-345.

102

103

CHAPTERS
SUMMARY
Immune system abnormalities and infection have long been suspected as factors
that trigger autism (Rimland, 1964; Warren et al., 1986). However, before the work
reported here, it was unknown whether T or B cell abnormalities played a dominant role
in the disease, if there was expansion of specific T cell clones, or if autistic individuals
responded abnormally to any specific pathogens. The involvement of T or B cells in
autism was explored in this work by examining the expression of cytokine markers of T
or B cell immune responses. Later studies examined if T cell clone expansion occurs in
autism by assessing the expression of all 24 major T cell receptor (TCR) V-P chain genes
in autistic and normal individuals. Finally, the potential link between T cell-mediated
autoimmunity, infectious agents, and autism was explored by examining T cell
proliferation in response to antigens derived from a panel of pathogens. The results of the
studies reported here provide new insights into this complex disease.
My results demonstrating elevated levels of interleukin type 2 (IL-2) and
interferon-y in autism suggest that T cells rather than B cells are involved in the disease.
Since IL-2 and interferon-y are markers of CD4+ T cell activation, the elevated
expression of these cytokines indicates that activated CD4+ T cells play a role in the
disease. Activation of CD4+ T cells is also known as a Th 1 type immune response and
activation of B cells is termed a Th2 response. The finding of a Th l immune response in
autism is significant because treatment strategies for Thl and Th2 responses differ.
Therapy for Th l responses involves administration of cytokines, such as IL-4, that are

elevated in Th2 type responses (Romagnani, 1995, 1996, 1997). This may be a
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productive avenue to explore for treatment of autism, a disease in which no effective
treatments are available.
The TCR V-P chain repertoire was found to be altered in autistic patients, and this
finding provided the clear evidence for the expansion of specific T cell clones. Using
competitive reverse transcription-polymerase chain reaction (RT-PCR), I quantified the
abundance of mRNA of each of the 24 major TCR V-P chains in autistic and normal
individuals. This is the first time a study of this scope has been performed in the
investigation of autism. As a group, autistic individuals express significantly higher
levels ofV-P 13 and lower levels of V-P 19 and 22. These results suggest that there is
biased expression of specific T-cell clones and support the hypothesis of altered T cell
function in autism.
The antigen-presenting human leukocyte antigen (HLA) DR4 or ORI allele
occurs frequently in autistic individuals. I examined the possible association between
these HLA DR molecules and T cell clone expansion by searching for an association
between these alleles and the expression of specific TRC V-P chains. HLA DR4- or
DR 1-postive autistic individuals (n = 7) showed significantly elevated V-P 13 expression
compared to normal individuals (n = 5). This result highlights the role played by these
HLA DR molecules in the disease. There was no difference in V-P 19 and 22 expression
between the DR4- or ORI-positive normal and autistic individuals. It appears that the
expansion ofV-P 13-expressing T cell clones is favored by HLA DR4 or DRl , whereas
deletion ofV-P 19 and 22 is independent of the HLA DR4 or ORI alleles.

If the expansion of V-13 13 is a general feature of autism, it may open a path
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for the treatment of the disease. V-13 13-expressing clones could be blocked through
immune therapy to potentially ameliorate disease symptoms. Moreover, the expansion of
V-13 13-expressing clones may serve as the first physiologically based diagnostic tool for
autism.
The final portion of this dissertation explored the possibility that infections by
certain agents may contribute to autism. Epidemiological studies have linked infections
and autism (Deykin and Macmahon, 1979). The hypothesis that autistic individuals
demonstrate an altered immune response to some infectious agents was examined by
observing T cell proliferation in response to a panel of T cell epitopes. These synthetic
peptide epitopes represented the major T cell epitopes of a list of pathogens implicated in
the development of autism. Comparison of a group of 24 autistic and 18 normal subjects
did not show a reduced T cell proliferative response in autistic patients to peptides
derived from rubella virus, herpes simplex virus type 1 (HSV-1), cytomegalovirus
(CMV), or tetanus. The only difference between groups that was detected was an
enhanced response to the influenza A virus epitope (matrix (M) protein) in autistic
subjects. Therefore, these results do not provide support for the idea that a lower immune
response to infectious agents plays a significant role in the disease. It is important to
realize, however, that comparisons were made between the group averages of autistic and
normal ·subjects and that widely varying individual responses were seen in each group. It
remains possible that some cases of autism are caused by infectious agents, as suggested
by previous epidemiological studies. However, if these cases occur at low frequency,
they would be undetected because they would not significantly affect the average group

response. If autism indeed is a multifactorial disease, teasing out any individual factor
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becomes difficult.
One of the most striking findings in the immunogenetics of autism is the strong
association of HLA DR4 or DRl with the disease. One postulate for this association is
molecular mimicry between these antigen-presenting molecules and sequences found in
some common pathogens. The Escherichia coli (E. coli) dna J protein and EBV gp110
are both significant antigens of these infectious agents (Roudier et al., 1988, 1989; Ikeda
et al., 1996) and both possess an amino acid sequence that is nearly identical to a critical
region of the DR4 or DRl gene products.
Results reported in Chapter 4 of this dissertation failed to provide support for the
hypothesis of molecular mimicry between HLA DR4 or DRl and E. coli dna J or EBV
gpl10. No relationship between possession of the HLA DR4 or DRI and the ability to
respond to the E. coli and EBY epitopes was detected in any group examined. There were
no differences in response to these peptides related to the DR4 or ORI allele. The same
caveat holds in this study of the response to HLA DR4- and DRl-like peptides as for the
investigation of the response to pathogen-derived peptides: a comparison of group
averages will fail to detect a small number of cases of autism that result from immune
tolerance of E. coli or EBY in DR4- or DRl-positive subjects.
What do the results of this dissertation say about the etiology of autism? First, it is
essential to realize that autism is likely to be a multifactorial disorder; no one cause is
responsible for autism in all affected individuals. Two leading postulates for causative
factors in autism are autoimmunity and infectious agents. My results provide support for
a role of autoimmunity in the disease, but failed to find evidence for the influence of

specific pathogens. Activation of CD4+ T cells is a hallmark of T cell-mediated
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autoimmunity. Therefore, my observation that many autistic individuals have activated
CD4+ T cells suggests the involvement of autoimmunity in the disease. Significantly,
there appears to be an expansion of specific T cell clones in autistic individuals. This was
demonstrated by the augmented expression of one V -� 13 mRNA. A similar situation
occurs in the autoimmune diseases rheumatoid arthritis and multiple sclerosis where
mono- or oligoclonal T cell expansion is observed (Urban et al., 1988; Jenkins et al.,
1993). There are many models that can incorporate these observations into the etiology of
autism, but at this stage, all are speculative. The proposal I favor merges the results of
this dissertation with the observation that in animal models activated T cell clones in
peripheral blood can cross the blood-brain barrier (Wekerle et al., 1986). I propose that
activated peripheral blood T cells cross the blood-brain barrier where they recognize CNS
components as antigens. These activated T cells are predicted to release IL-2 and other
cytokines that recruit inflammatory cells, macrophages, effector T cells, and antigen
presenting cells. These cells would produce CNS tissue damage. In combination with
autoimmune attack on the CNS, this would create CNS lesions that cause autism. In
support of these ideas, in animal models of multiple sclerosis, specific T cell clones
activated in peripheral blood are also found within CNS tissues.
Obvious questions that stem from this model is whether T cell infiltration can be
demonstrated in autism and, if so, whether T cell infiltration is involved only in autism or
plays a more general role in other neurological disorders. An animal model of autism,
which is currently not available, would greatly accelerate research into these and related
questions.

Both Todd (1986) and Warren et al. (1987) proposed immune tolerance as an
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alternative mechanism to autoimmunity in the etiology of autism. Autistic individuals
often exhibit decreased immune functions of T cells (Warren et al., 1986), B cells
(Warren et al., 1986), natural killer cells (Warren et al., 1987), immunoglobulin A
(Warren et al., 1997), and complement C4B (Warren et al., 1995). My results did not
indicate a reduced T cell proliferation in response to any single peptide in autistic
individuals, but did show that there was a generally lowered T cell proliferation in
autistic subjects whether untreated or challenged with peptide. It is likely that reduced T
cell function would adversely affect the immune competence of autistic subjects. This
widespread reduction in immune responsiveness, whatever its cause, may play a more
important role in autism than immune tolerance to specific pathogens. Given the
proposed mulitfactorial nature of autism, autoimmunity and a generally depressed
immune system function are not mutually exclusive possibilities for the development of
the disease.
The results of this dissertation open more questions than they answer and a
comprehensive understanding of the disease remains a distant hope. Some of my results,
however, especially the finding of specific T cell clone expansion, may pave the way to
diagnosis and, more optimistically, therapy for the disease.
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PHA STIMULATION OF CRYOPRESERVED PBMC:
A METHOD TO AMPLIFY T CELLS
ABSTRACT
An important technical issue in the analysis of T cell populations involved in
human T cell-mediated diseases is the limited number of these cells in affected tissues
(Fujihashi et al., 1996; Jenkins et al., 1993). Amplification of primary T cell populations
by mitogen treatment is a commonly used approach to circumvent this problem. Often,
the primary populations of T cells are cryopreserved prior to mitogen stimulation.
However, there are conflicting reports regarding whether amplification of primary T cell
populations skews the distribution of T cell subtypes. In this communication, the affect of
phytohemagglutinin (PHA) stimulation of freshly isolated or cryopreserved peripheral
blood mononuclear cells (PBMC) on the distribution of T cell subtypes was examined. T
cell receptor (TCR) V-P chain expression was used to assess the distribution of T cell
subtypes. The expression of all the 24 major TCR V-P chains was analyzed by
competitive reverse transcription-based polymerase chain reaction (RT-PCR) in the
PBMC of three subjects. The results show that PHA stimulation of fresh or cryopreserved
PBMC did not significantly alter the TCR V-P chain repertoire of the cells.
INTRODUCTION
Analysis of TCR repertoires is used to identify T cell clones that are activated
during infection and disease (Ohga et al., 1999; Than et al., 1999). The expansion of a
single or limited number of T cell clones occurs in many human autoimmune disorders

(Wucherpfennig et al., 1995; Abe et al., 1993; Moller et al., 1988). The identification
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ofthese clones offers the hope oftherapy based on deletion ofthe specific activated
clones (Urban et al., 1988; Vandenbark et al., 1989). The variable region ofthe J3 chain
(V-J3) is the most commonly examined molecular marker ofT cell identity (Arche-Orbea
et al., 1988; Keystone et al., 1995; Posnett et al., 1990). The small number ofT cells that
can be recovered from either affected tissues or the peripheral blood is a limiting factor in
the study ofautoimmune and other T cell-based disorders. One approach to circumvent
restricted T cell number is to amplify the T cell population by treatment with a mitogen
such as PHA. A concern with such an approach is that particular clones may be
selectively amplified or lost, creating an altered population that poorly mirrors the
original clonal diversity. There are conflicting reports as to whether this is a real or
hypothetical issue. Using flow cytometry and a limited list ofmonoclonal antibodies
available for TCR V-J3 chain, Davey and Munkirs (1993) found that treatment ofPBMC
with the mitogen ConA skewed V-J3 chain expression compared to the starting population
ofcells. However, when using PHA to stimulate growth, Jason et al. (1996) found that
there was an unbiased representation ofclones in the expanded population.
The studies reported in Chapter III ofthis dissertation required a significant
number ofT cells from a large group ofautistic and control individuals. This necessitated
some method ofincreasing T cell number. The studies presented in this appendix
examined ifeither oftwo methods ofT cell expansion produced an unbiased V-J3
repertoire identical to that ofthe initial T cells. The expression ofthe 24 major V-J3
chains was studied using the sensitive technique ofcompetitive RT-PCR. The results

show that PHA stimulation of either fresh or cryopreserved PBMC did not alter the
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repertoire of V-P chain expression. These results justify the use of PHA-stimulated fresh
or cryopreserved cells in the studies of this dissertation.

MATERIALS AND METHODS
Isolation of Total RNA
Blood was drawn from three volunteers into vacutainer tubes and PBMC were
isolated by histopaqua (Sigma, St. Louis, MO) density centrifugation. The PBMC were
divided and placed into three treatment groups: I) fresh PBMC (5 x 106); 2) fresh PBMC
5
(5 x 10 ) cultured with 10 µg/ml PHA (Gibco BRL, Grand Island, N.Y.) for five days;

and 3) PBMC (5 x I05 ) cryopreserved at -70°C for IO days, thawed, then stimulated with
PHA as above. Total RNA was isolated using Trizol (Gibco, Gaitherburg, MD) from 5 x
I06 primary or PHA-stimulated PBMC, and then dissolved in 30 µl of sterile H2 0. Total
RNA concentration was measured by absorbance at 260 nm.
cDNA Synthesis and RT-PCR
To synthesize cDNA, 2 µg of total RNA was reverse-transcribed in a 20-µl
reaction mixture at 37°C for two hours according to the manufacturer's instructions
(Promega, Madison, WI). The resulting cDNA was divided equally into 24 tubes, each
containing a 5' TCR V-P-specific sense primer, a common 3' TCR V-P C antisense
primer, I00 femtomoles of a reference cDNAs (also called competitor), and the other
PCR components described in Chapter III of this dissertation. PCR was performed in a 15
µl reaction volume using an initial 5 minutes of denaturation at 94 °C followed by 30

cycles of the profile: 1 minute at 94 °C, 1 minute at 58 °C and 1 minute at 72 °C. TCR
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V-13 21 was used to optimize competitive RT-PCR, and these conditions were applied to

all 24 V-13 chains. PCR products were analyzed by electrophoresis through 2% agarose
gels.
Analysis of PCR Products

Analysis of PCR products was performed according to Spinella and Robertson
(1994). Briefly, a photograph of the agarose gel was converted to a digital image. The
image was analyzed using the digital processing program from Biosoft Inc. (Ferguson,
MO). The intensities of endogenous cDNA products were normalized relative to that of
the most intense band. A similar normalization was performed for the reference cDNA
amplification products, each 86-bp larger than the corresponding endogenous bands. The
ratio between the normalized values of each endogenous band relative to its
corresponding reference band was calculated and termed the relative expression index
(REI).
Statistical Analysis

The V-13 repertoires of each treatment regimen were arranged in descending order
of REI values. For each treatment in each individual, Spearman's rank test was used to
calculate an rs value [rs= 1- (6 x (Id?)/(n3-n))], where di represents the rank difference
between the repertoires of fresh PBMC vs the repertoires of any other two treatments,
and n is the sample size. Then, Spearman's t test was employed according to Harnett
(1982) to test the significance of differences between treatments. In Spearman's t test, t=

rs x [(n-2)/(1-r/)]
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,

while r5 represents the rank sum and n is the sameple size. The t
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value was used to assess the significance of differences (p value).

RESULTS AND DISCUSSION
Analysis of V-/3 Chain Repertoires by
Competitive RT-PCR
V-P chain expression was analyzed by competitive RT-PCR. This technique has
the advantages of sensitivity relative to Southern analysis and flow-cytometry, two
methods traditionally employed for these studies. Optimizations of RT-PCR were
performed using V-P-21 as a representative V-P chain. Two µg of total RNA from
PBMC were used to synthesize cDNA. Aliquots (2 µl) of the cDNA were co-amplified
with varying amounts of reference cDNA. Reference cDNA is a V-P-21 gene modified
by insertion of an 86-bp sequence. This distinguishes reference and endogenous cDNA
amplification products. Amplification was carried out for 30 cycles. The amount of
starting endogenous cDNA is determined in one of two ways. In an experiment, such the
one shown in Figure 6.1, the lane that demonstrates equal intensity of the reference and
endogenous cDNA bands gives the amount of starting endogenous cDNA as this equals
the known starting amount of reference cDNA. In Figure 6.1, this is lane 5 and the
amount of endogenous cDNA therefore is 25 femtomoles. In large-scale assays involving
many samples, such as those used to analyze the 24 major V-P chains from dozens of
individuals, optimization for all samples is impractical. In this case, one talces advantage
of the linear relationship between the log ratio of reference/endogenous band intensity to
the log of reference cDNA molecules. This relationship for the PCR shown in panel A of
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Fig. 6.1. Competitive RT-PCR analysis ofTCR V-P 21 expression. Panel A. Two µl
of the endogenous cDNA were co-amplified with 2 µl of reference cDNA prepared as a
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B. Quantitative analysis of the data plotted in panel A.

Figure 6.1 is demonstrated in panel B of the same Figure. In experiments, such as
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those presented in Chapters II and III, the log10-transformed ratio of reference to
endogenous bands is determined and the amount of endogenous cDNA is derived from
the x intercept of this ratio.
Having established conditions for the amplification of TCR V-P-21, the assay was
extended to all 24 V-P clones. Two µl of endogenous cDNA and IO femtomoles of
reference cDNA were aliquoted into 24 tubes and amplified by PCR under identical
conditions. Figure 6.2 shows a gel displaying a typical PCR using cDNA derived from
fresh PBMC of a single donor. In each lane, two DNA bands were generated, the smaller
one from endogenous cDNA and the larger one from the reference cDNA. As expected,
the products from reference cDNAs were 86-bp larger than their corresponding
endogenous products.
Analysis of the relative levels of expression of each V-P chain was performed
using software from Biosoft, Inc. The analysis compares the densities of the endogenous
and reference cDNA products in each lane and normalizes these relative to the highest
endogenous/reference cDNA ratio observed in an individual. These normalized ratios,
termed the relative expression index (REI), assess the relative expression level of each V
P chain in an individual. Analysis of the PCR shown in Figure 6.2 indicated that V-P 5, 8,
and 13 were the predominant V-P chains expressed in this individual (Figure 6.3).
Comparison of the TCR V-/3 Repertoire
from Fresh and Amplified PBMC
V-P chain expression was compared in fresh PBMC, fresh PBMC directly

12l)

Lane ,

2, � s 6 1s910111211,11J141s16111s1920 21222324

Fig. 6.2. RT-PCR of 24 TCR V-13 mRNAs expressed in PBMC of donor l . The total
RNA was extracted from peripheral blood mononuclear cells and cDNA was synthesized
in vitro using reverse transcriptase at 3 7°C overnight. The resulting cDNA was used as
the template to set up PCR. PCR Then, the PCR products were run on 2% DNA agarose
gel for I hour, stained by ethidium bromide and visualized under UV light. (Lanes l-12
represent TCR V-13 l -12; Lane M representsl-kb DNA size marker and 500-bp DNA size
band is the major marker to judge the RT-PCR products; Lanes 13-24 represent RT-PCR
products from TCR V-13 13-24.) All RT-PCR products were identified to have the correct
sizes and the endogenous products were confirmed to be constantly 86-bp smaller than
the corresponding reference cDNA products.
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Figure 6.3 shows the REis of 24 V-P chains from fresh or PHA-stimulated PBMC taken
from the same individual analyzed in Figure 6.2. This analysis shows that V-P 2, 5, 8,
and 13 were the predominant clones in all three PBMC preparations. Visual inspection of
the results indicates that PHA treatment alone or coupled with cryopreservation did not
alter the V-13 repertoire. PBMC preparations from two additional donors were treated
under the same three conditions (Figures 6.4 and 6.5). Once again, visual inspection
showed that the expression repertoire was not altered by PHA treatment alone or PHA
treatment following recovery from cryopreservation. A different pattern of V-P chain
expression was observed in each of the three normal subjects (Figures 6.3, 6.4 and 6.5).
A more rigorous analysis of the data was made using Spearman's rank test. This
test measures the significance of differences in rank of V-P chain expression under the
three experimental conditions. A p value of less than 0.01, which indicates no significant
difference, was found in each subject for comparisons between V-P expressions in fresh
PBMC relative to PBMC stimulated by PHA under either treatment regimen (see Table
6.1).
These findings of the study are significant because they show that long-term
storage of T cell populations and their subsequent amplification is possible without
skewing the original composition of T cell subtypes.
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Table 6.1
Spearman's Rank Test ofTCR V-P Expression in Three Donors
Fresh vs PHA-Stimulated
a
fs

tb

1

0.766

5.59

2

0.813

6.56

3

0.774

5.73

Donor

pc

a

tb

pc

< 0.01

0.744

5.23

<0.01

<0.01

0.849

7.55

<0.01

0.884

8.89

<0.01

<0.01

The rank sum values of Spearman's rank test.
t values of Spearman's rank test.
cp value of Spearman's rank test.

8

b

Fresh vs Cryopreserved
fs
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OPTIMIZATION OF A PEPTIDE-MEDIATED
T CELL PROLIFERATION ASSAY
ABSTRACT
Optimal conditions were established for T cell proliferation stimulated by
synthetic peptide epitopes. The effect ofvarying the epitope concentration, the type and
amount ofcytokines, and the concentration of serum were examined. The optimized
assay utilized peripheral blood mononuclear cells (PBMC) cultured with 10% fetal
bovine serum, 30 international units (IU)/ml interleukin type 2 (IL-2), and 1 µM synthetic
peptide.
INTRODUCTION
The T cell proliferation assay is an important experimental tool to assess the
response ofT cells to antigens (DuPont et al., 1985; Rychlikova et al., 1971; De Graeff
Meeder et al., 1991). Current applications ofthe assay often employ synthetic peptide
mediated epitopes to stimulate T cell proliferation (Schrader et al., 1991). It is critical to
establish optimal conditions for the assay, especially when using synthetic epitopes,
which often are only weakly antigenic (Bromelow et al., 1997; Yang et al., 1995;
Durinovic-Bello et al., 1996). The influence of peptide concentration, the type and
amount of cytokines, and serum levels on the T cell proliferation assay were investigated
(Bertram et al., 1997; Hao et al., 1986; and Lamers et al., 1992).

MATERIALS AND METHODS
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Synthetic Peptide Epitopes
Ten peptides derived from known or predicted epitopes of pathogens potentially
involved in autism were synthesized at the Utah State University Biotechnology Center.
The peptides were purified by reverse-phase high performance liquid chromatography,
and diluted in RPMI-1640 (RPMI Inc., Cellgro, VA). Their amino acid sequences are
listed (see Table 4.1 of chapter IV).

T Cell Proliferation Assay
PBMC were isolated from fresh blood of normal healthy donors by histopaque
(Sigma, St. Louis, MO) density centrifugation. PBMC were cultured in 96 well plates
using RPMI-1640, fetal bovine serum (usually 10%), and synthetic epitopes. When
recombinant cytokines were included, they were added 24 hours after beginning cell
culture (Chain et al., 1987). Five days after adding synthetic peptide, 2 µl of 3H
thymidine (1 µCi; Moravek Biochemicals. Inc., Brea, CA) was added to each well, cells
were incubated for 3 hours, then transferred to a filter membrane (Packard Instrument
Inc., Dower Grove, IL) using a cell harvesting device (Micromate-196, Packard
Instrument Inc., Dower Grove, IL). The unincorporated 3 H-thymidine was removed by
vacuum filtration, and the counts associated with the cells determined using a direct P-ray
counte� (Matrix™-96, Packard Instrument Inc., Dower Grove, IL). Proliferation indices
were expressed as the ratios of the average counts per minute (cpm) from triplicate
antigen-containing test wells to the average cpm of triplicate control wells without
antigen.

RESULTS AND DISCUSSION
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Peptide Concentration
The effect of 4 different synthetic peptides, rubella capsid, rubella E2, HSV-1 ge
l and tetanus toxin on T cell proliferation was investigated in cells cultured without any
added cytokines. Each peptide was added at 5 different concentrations that ranged
between 1 x 10-3 µM - 10 µM. Typical peptide concentrations used in T cell proliferation
assays range between 0.01 and 1 µM (Orlik et al., 1996; Mayer et al., 1996). The
proliferation index at any peptide concentration never exceeded 1.6. Later studies (see
below) demonstrated that a cytokine must be added to the cells to increase the
proliferation index to more significant values. Nonetheless, the peptide dose-response
relationships shown in Figure 7. I indicate that for most peptides a concentration of I µM
was the most effective. Increasing the concentration to IO µM almost always was
inhibitory.
Cytokines
Cytokines play essential roles in T cell proliferation (Chain et al., 1987). The
effect of IL-2, interleukin type 3 (IL-3), interleukin type 4 (IL-4), interleukin type 6 (IL6), interleukin type 12 (IL-12), platelet-derived growth factor (PDGF) on T cell
proliferation without added peptide was investigated. As shown in Figure 7.2, IL-2 was
the most potent cytokine for T cell proliferation. For peptide-stimulated T cell
proliferation, a cytokine concentration that stimulates cell growth roughly between 2- and
10-fold is optimal. Increasing the proliferation index above these values produces a low
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Fig. 7.1. Effect of peptide concentration on the T cell proliferation assay. Four synthetic peptides
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were used. For each peptide, five concentrations (10, l, 0.1, 0.01 and 0.001 µM, from left to right)
were examined for their effects on the T cell proliferation assay.
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signal-to-noise ratio associated with addition of peptide. For this reason, a

135

concentration 30 IU/ml of IL-2 in the culture medium was chosen as the standard for
assays of this dissertation.
Interaction between Peptide and IL-2
The effect of IL-2 addition (30 IU/ml) on T cell proliferation assay increased the
sensitivity of the assay, and the stimulation index derived from 10 synthetic peptide
epitopes used in this dissertation is shown in Figure 7.3. There is some disagreement on
what constitutes a significant level of enhanced proliferation, with most researchers
placing the minimum value of the proliferation index at either 1.5 or 2.0. Applying a
value of 2.0, Figure 7.3 indicates that the peptide of Epstein-Barr virus (EBY) gp110 and
tetanus toxin induced significant proliferation, but only when PBMC were cultured with
IL-2. A significantly difference was found between with added IL-2 (30 JU/ml) and
without added IL-2 by Student's t test (p < 0.01).
Serum Concentration
Published reports employing the T cell proliferation assays call for serum levels
between 1-10% (Orlik et al., 1996). The effect of fetal bovine serum concentrations of
1% and 10% on T cell proliferation stimulated with 3 different peptides was examined
and the results are shown in Figure 7.4. A 10% serum concentration was essential for the
assay.
The Optimized Assay
Based on the results described above, the standard T cell proliferation assay
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employed in this thesis utilized PBMC cultured with l 0% serum, 30 IU/ml IL-2, and
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l µM synthetic peptide.

REFERENCES
Chain B., McCafferty I., Wallace G., and Askenase P.W. (1987) Improvement of the in
vitro T cell proliferation assay by a modified method that separates the antigen
recognition and IL-2-dependent steps. J !mmunol. Methods 99, 221-228.
Bertram E.M., Jilbert A.R., and Kotlarski I. ( l 997) Optimization of an in vitro assay
which measures the proliferation of duck T lymphocytes from peripheral blood in
response to stimulation with PHA and ConA. Dev. Comp. /mmunol. 21, 299-310.
Bromelow K.V., Souberbielle 8., Alavi A., Goldman J.H., Libera L.D., Dalgleish A.G.,
McKenna W.J. (1997) Lack of T cell response to cardiac myosin and a reduced
response to PPD in patients with idiopathic dilated cardiomyopathy. J
Autoimmun. 10, 219-227.
De Graeff-Meeder E.R., van der Zee R., Rijkers G.T., Schuurman H.J., Kuis W., Bijlsma
J.W., Zegers B.J., and van Eden W. (1991) Recognition of human 60 kD heat
shock protein by mononuclear cells from patients with juvenile chronic arthritis.
Lancet 337, 1368-1372.
DuPont E., Huygen K., Schandene L., Vandercruys M., Palfliet K., and Wybran J. (1985)
Influence of in vivo immunosuppressive drugs on production of lymphokines.
Transplantation 39, 143-147.
Durinovic-Bello I., Hummel M., and Ziegler A.G. (1996) Cellular immune response to
diverse islet cell antigens in IDDM. Diabetes 45, 795-800.

Hao X.S., Le J.M., Vilcek J., and Chang T.W. (1986) Determination of human T cell

139

activity in response to allogeneic cells and mitogens. An immunochemical assay
for interferon-y is more sensitive and specific than a proliferation assay. J
Immunol. Methods 92, 59-63.
Lamers C.H., van de Griend R.J., Braakman E., Ronteltap C.P., Benard J., Stoter G.,
Gratama J.W., and Bolhuis R.L. (1992) Optimization of culture conditions for
activation and large-scale expansion of human T lymphocytes for bispecific
antibody-directed cellular immunotherapy. Int. J Cancer 51, 973-979.
Mayer S., Scheibenbogen C., Lee K.H., Keilholz W., Stevanovic S., Rammensee
H.G., and Keilholz U. (1996) A sensitive proliferation assay to determine the
specific T cell response against HLA-A2. l -binding peptides. J Immunol.
Methods 197, 131-137.
Orlik 0., and Splitter G.A. (1996) Optimization of lymphocyte proliferation assay for
cells with high spontaneous proliferation in vitro: CD4+ T cell proliferation in
bovine leukemia virus infected animals with persistent lymphocytosis. J
Immunol. Methods 199, 159-165.
Rychlikova M., Demant P., and Ivanyi P. (1971) Histocompatibility gene organization
and mixed lymphocyte reaction. Nat. New Biol. 230, 271-272.
Schrader J.W. (1991) Peptide regulatory factors and optimization of vaccines. Mo!.
Immunol. 28, 295-299.
Yang P.M., Hwang L.H., Lai M.Y., Huang W.L., Chu Y.D., Chi W.K., Chiang B.L.,
Kao J.H., Chen P.J., and Chen D.S. (1995) Prominent proliferative response of
peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein

of hepatitis C virus in patients with chronic hepatitis C. Clin. Exp. Immunol.

101, 272-277.

140

141
CURRICULUM VITAE
YONG(ROGER)HU
Department of Biology/Center for Persons with Disabilities
Utah State University
Logan, Utah 84322-5500
Tel: (435) 797-7029
Fax: (435) 797-4054
email: sls81@cc.usu.edu
EDUCATION
Bachelor of Medicine, Hubei Medical University, Wuhan, China
Master of Medicine in Microbiology & Immunology, Hubei Medical
University, China
1994-present Ph.D. Candidate, Utah State University, Logan, UT

1981-1986
1986-1989

POSITIONS
Lecturer of Oncovirology, Virus Research Institute, Hubei Medical
College, Wuhan, China
Research Associate, Department of Pathology, The University of
1992-1993
California, San Diego, CA
Research Fellow, Department of Biology, Utah State University, Logan,
1993-1994
UT
1994-present Research Assistant and Teaching Assistant, Department of Biology, Utah
State University, Logan, UT
1989-1992

HONORS & AWARDS
1982
1991

National Distinguished Medical Student Award, Hubei Medical College,
Wuhan, China
Recipient of Chinese National Science Foundation Grant, Wuhan, China

PROFESSIONAL ORGANIZATIONS
American Society for Virology (1997-present)
Society of Chinese Bioscientists in America (1993-present)
Chinese Society for Microbiology and Immunology ( 1989-present)
Chinese Society for Tumor and Tumor Markers ( 1990-preesnt)

PUBLICATIONS AND PRESENTATIONS

142

Hu Y. (2000) Altered T cell-mediated immunity and infectious factors in autism. Ph.D.
Dissertation, Logan, UT.
Hu Y., Warren R., Maciulis A., Burger R., Torres A., Warren L., and Odell D.
Expression of the cytokines interferon-y and IL-2 suggests a T cell-mediated Thl
response in autism. J Aut. Dev. Dis. In revision.
Hu Y., Warren R., Maciulis A., Burger R., Warren L., and Odell D. Preferential
expression of the T cell receptor V-P chain subtype V-P 13 in autism. Submitted.
Hu Y., Warren R., Maciulis A., Burger R., Warren L., and Odell D. Peripheral T cell
responsiveness to peptides of pathogens possibly involved in autism. In
preparation.
Hu Y. (1999) Altered T cell-mediated immunity in autism and identification of
pathogens possibly involved in the disease. Neuroimmunology Branch, National
Institutes of Health, Bethesda, MD. January 26, 1999 (Seminar).
Hu Y. (1999) Identification of pathogens possibly involved in autism by T cell
proliferation assay. Department of Immunology, American Red Cross, Bethesda,
MD. January 27, 1999 (Seminar).
Hu Y. (1999) Studies of cytokine and T cell receptor gene expression in patients with
autism. Department oflmmunology, University of Chicago, Chicago, IL. March
26, 1999 (Seminar).
Hu Y. (1999) Immune system defects in the etiology of autism. Department of
Immunology, Bechman Research Institute, Los Angeles, CA. April 10, 1999
(Seminar).
Hu, Y R. Burger, A. Maciulis, A. Torres, J. Billingsley, N. Bergeron, L. and Warren, D.
Odell. (1999) T cell responses to peptides of pathogens suspected in autism.
American Society for Virology: 18th Annual Meeting. Amherst, MA. pp. 168.
(Abstract).
Hu, Y. (1998) Analysis of T cell receptor V-P expression in patients with autism by
·competitive RT-PCR. Annual Meeting of Experimental Biology 98'. The FASEB
J 12, pp. 1096. (Abstract).
Hu Y. (1998) A comparative study of human T Cell receptor V-P gene expression by
RT-PCR.lnterrnountain Paper and Poster Symposium, Logan, UT. (Abstract).

Hu Y., Shen Y. (1992) In: Essential Oncovirology. Hubei Medical College, Wuhan,
China.

143

Hu Y., Hsiang J.M., Zhao W.X. (1991) Ras oncogene. Chin. Clin. Oneal. 18, 187-189.
Hu Y., Chao W.X., and Hsiang J.M. (1991) A comparative study of plasmid DNA
extraction. J Hubei Med Coll. 12, 104-106.
Hu Y., Li H.Q., and Hsiang J.M. (1990) Human Papilloma Virus infections: pathogenesis
and clinical therapy. J Med 13, 212-215.
Hu Y. (1989) A primary study on the synergic roles of HPV-16 and c-Ha-ras-1 oncogene
in the etiology of human cervical carcinoma. Master Thesis, Hubei Medical
University, Wuhan, China.

